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ABSTRACT 
 
 Preclinical results support the use of N-methyl D-aspartate receptor (NMDAR) 
modulators for cognition enhancement therapeutics. Pregnenolone sulfate (PregS) is a 
neuroactive steroid derived from cholesterol that augments long term potentiation (LTP) 
in hippocampal slices and improves memory performance in rats and mice.  At 
micromolar concentrations, PregS is a subtype selective positive allosteric modulator of 
NMDARs at NR2A and NR2B containing receptors, and at concentrations ranging from 
pM - nM induces NMDAR-dependent dopamine release in the striatum and from striatal 
synaptosomes. In this report, we observe that micromolar [PregS] induces an increase in 
levels of neuronal intracellular calcium ([Ca2+]i) and surface NMDARs in cortical 
neurons.  Moreover, our results show that PregS stimulated upregulation of surface NR1 
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subunits in cortical neurons is dependent on NMDARs but independent of channel 
activity.  As PregS has been detected in brain at bulk concentrations of 0.1 nM to 5 nM, 
we asked whether low, picomolar concentrations of PregS might alter [Ca2+] levelsi.  We 
report here that PregS increases [Ca2+]i signal in cortical neurons in a voltage-gated Na+ 
channel and NMDAR-NR2B dependent manner with an EC50 of ~2 pM, at least 6 orders 
of magnitude higher affinity than its rapid potentiating effect upon the NMDAR-
mediated ionotropic response, and within the range of PregS detected in bulk brain tissue.  
Additionally, calcium  (Ca2+) activation of cyclic AMP response element binding protein 
(CREB) is critical to the protein synthesis-dependent component of LTP and important in 
associated behavioral measures of learning and memory.  Increased [Ca2+]i levels are 
known to induce CREB activation and we now show that 50 pM PregS induces a 44 ± 
13% increase in the ratio of pCREB to total CREB that is dependent upon ERK signaling 
and canonical excitatory synaptic transmission: this includes voltage gated Na+ channels, 
NMDARs, and voltage-gated Ca2+ channel activation. The results taken together indicate 
that PregS may be a useful platform for the development of high-affinity positive 
modulators of NMDAR-signaling that can be used as cognitive enhancers to treat a 
variety of neurological disorders: such as Alzheimer's disease, Parkinson's disease, and 
schizophrenia.
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Chapter 1 
Non-genomic Actions of PregS, a Neuroactive Steroid Modulator of Signal 
Transduction in the CNS1 
Introduction 
 This review provides an update on preclinical and clinical studies exploring 
multiple loci within the synapse as mediators of PregS action and as potential novel 
targets of neurosteroid-based therapeutics. The role of the neuroactive steroid PregS as a 
modulator of neural transmission remains an active area of investigation (reviewed in 
Gibbs 2006; Schumacher 2008).  Recent preclinical and clinical studies provide 
additional evidence that PregS may function as an endogenous neuromodulator, creating 
renewed interest in the identification of novel neuroactive steroid targets for 
pharmacological intervention. The goal of this review is to highlight recent significant 
progress on the function of neuroactive steroids in the central nervous system (CNS) and 
possible new directions in the future of PregS research.   
 30 years have elapsed since the first suggestion that PregS is an endogenous 
neurosteroid (Corpechot 1983). The term neurosteroid was coined by Etienne Baulieu to 
describe steroids that are synthesized from cholesterol in the central nervous system 
independently of the endocrine system (Baulieu 1997; Baulieu 2001). Steroids are 
capable of affecting a diverse range of cellular functions by binding to cytosolic and 
                                                
1 Psychopharmacology (2013/2014) Pregnenolone Sulfate as a Non-Canonical Modulator of the NMDA 
Receptor  
A Special Issue on Neuroactive Steroids in Memory of Robert Purdy 
Authors: Smith, CC, Gibbs, TT, and Farb, DH 
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nuclear receptors that bind to DNA and induce changes in gene transcription (Kawata 
2008; Marques 2009).  However, neurosteroids are also capable of modulating 
neurotransmission by non-genomic mechanisms (Gibbs 2006). Subsequent studies 
identified neuromodulatory effects of PregS on NMDA and GABAA receptors (Jo 1989; 
Wu 1991; Malayev 2002). PregS also modulates synaptic transmission by both 
presynaptic and postsynaptic mechanisms across multiple neurotransmitter systems 
(reviewed in Zheng 2009). There are now many lines of evidence, both clinical and 
preclinical, linking neuroactive steroids to central nervous system disorders including 
fetal alcohol spectrum disorder (Zimmerberg 1995), epilepsy (Budziszewska 1998; Hill 
2010;  Pierbone 2007), anxiety (Crawley 1983; Strohle 2002), depression (Uzunov 1996;  
Khisti 2000; Marx 2006; Girdler 2012; Wolkowitz 1999) and schizophrenia (Wong 2012; 
Marx 2009). The multiple potential targets for pharmacologic intervention by neuroactive 
steroids are comprehensively reviewed in: Valenzuela et al., 2008; Zheng et al., 2009; 
Reddy et al., 2010; and Marx 2010.  Recent preclinical research highlighted below 
provides new insight into neuroactive steroid modulation of synaptic function. 
Additionally, recent clinical studies discussed in the review indicate the therapeutic 
potential for neuroactive steroids in schizophrenia and cognitive dysfunction.  
 
PregS as an Endogenous Neuromodulator 
 PregS modulates NMDA, glycine, and GABAA receptors and acts as an agonist at 
calcium-permeable TRP channels, all with micromolar (10-6) potency (Wu 1991; Park-
Chung 1997; Wagner 2008).  PregS also exhibits a higher potency (10-9 to 10-12) mode of 
  
 3 
action in inducing neurotransmitter release in rat striatum (Sadri-Vikili 2008; Whittaker 
2008).  PregS potentiates synaptic LTP and enhances spatial memory in rat behavioral 
tests (Sliwinski 2004; Flood 1995), and inhibition of steroid sulfatase ameliorates deficits 
in spatial memory induced by septal-hippocampal lesions (Babalola 2012).  Conversion 
of the precursor pregnenolone (PREG) to PregS may in part underlie PREG efficacy in 
ameliorating cognitive deficits in schizophrenia (Marx 2009).  
 The known pharmacology of PregS is that it binds to and modulates receptors, 
induces neurotransmitter release, modulates synaptic efficacy, and modulates learning 
and memory in tissue models and in live animals.  Although there is an abundance of 
PregS pharmacology in the nervous system that has been collected over the past 15 years, 
its role as an endogenous neuromodulator and its de novo production in human and rat 
brain is still an active area of investigation.   
 
PregS biosynthesis and transport 
 The rate-limiting step for neurosteroid production is the transport of cholesterol 
from the cytoplasm to the mitochondrial matrix (Stocco 2001) by the steroid acute 
regulatory (StAR) protein (Clark 1994).  Following cholesterol translocation, the 
enzymatic synthesis of PregS occurs in two enzymatic steps, cleavage of the C20-22 
bond by cytochrome P450 side-chain cleavage (P450scc) enzyme to yield pregnenolone 
(PREG) and sulfation of the C3 hydroxyl group by sulfotransferase (SULT) enzymes 
(Mellon 2001). Message RNA (mRNA) for StAR (Furukawa 1998) and P450scc (Mellon 
1993) are present and co-localize in rat brain (Furukawa 1998).  RNA for P450scc was 
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detected in post-mortem human brain samples at equal levels in temporal lobe cortex, 
subcortical white matter and hippocampus, and was found to be expressed at higher 
levels in women than men (Watzka 1999). The human SULT gene family is divided into 
three groups according to sequence homology and substrate specificity (Falany 2006). 
The SULT2B1 isoforms are stereoselective for "-hydroxysteroids (Meloche 2001), and 
mRNA for the SULT2B1a isoform is present in rat brain and kinetic activity of the 
enzyme for pregnenolone was demonstrated (Kohkitani 2006). StAR, P450scc, and 
sulfotransferase protein localization to rat CA1 pyramidal neurons was demonstrated by 
immunohistochemistry (Kimoto 2001).  SULT2B isoform mRNA, protein or activity was 
not detected in surgically resected human temporal lobe (Steckelbroeck 2004). However, 
this analysis was limited to the temporal lobe, and it is known that SULT2B activity is 
lost upon cellular extraction (Falany 2006). The SULT4A1 isoform is highly expressed in 
human and rat brain tissue and localizes to neurons (Liyou 2003), however, the 
physiological substrate for SULT4 is unknown. Finally, an oligodendrocyte cell line 
derived from a human glioma expresses mRNA and protein PBR (a transporter protein 
that interacts with StAR) and P450scc, and is capable of synthesizing PregS de novo 
(Brown 2000).   
 PregS may also obtain access to the brain by transport across the blood-brain 
barrier (BBB) via specific transporters. Although PregS is charged and would not be 
expected to cross cell membranes, multiple isoforms of organic anion transporters 
(OATP) are expressed in human brain (Steckelbroek 2004) and could transport PregS 
across the BBB.  Sulfated steroids including estradiol sulfate (Wood 2003) and PregS 
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(Wang 1997) are capable of gaining access to the brain from the periphery. The presence 
of mRNA and protein for an organic solute transporter (with high substrate specificity for 
PregS) expressed in purkinje cells and hippocampal cells in humans lends further 
evidence in support of PregS production in the human central nervous system (Fang 
2010).  The existence of PregS-specific efflux transporters in steroidogenic cells provides 
supporting evidence that on-demand, localized release of sulfated steroids (Fang 2010) is 
a plausible mechanism for endogenous PregS modulation of neurotransmission. 
 
PregS and PREG Bulk Tissue Levels 
 Using an enzyme-linked immunosorbant assay (ELISA) with a detection limit of 
0.3 ng/g Higashi et al. (2003) determined that PregS was present in 1/10 rat brains at 0.4 
ng/g,  Liere et al. (2004) also observed PregS at 0.2 and 0.8 ng/g in 2/5 rat brains using 
GC-MS analysis of samples with a detection limit of 0.15 ng/g. Moreover, two post-
mortem human brain tissue samples contained PregS at 1.85 ng/g in cerebellum and 1.11 
ng/g in frontal cortex (Liere 2004). Other reports failed to detect PregS in rat brain either 
by nanoscale liquid chromatography-electrospray mass spectrometry with a detection 
limit of 0.3 ng/g (Liu 2003) or by anion exchange chromatography and gas 
chromatography mass spectrometry (GC-MS) with a detection limit of 0.05 ng/g (Ebner 
2006).  The GC-MS method of detection for PregS was the most sensitive, with a limit of 
detection (LOD) 0.05 ng/g. If PregS is evenly distributed in the bulk tissue, with 1g = 
1mL, the LOD for PregS is ~0.1 nM. Therefore if PregS is present at concentrations 
below 0.1 nM, for PregS to enact physiological changes it must have potency in the pM 
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range.  The immediate precursor to PregS, PREG is found in both rat and human brain as 
well as plasma. Utilizing liquid chromatography coupled with tandem mass spectrometry 
(LC-MS/MS) Caruso et al. (2013) determined that PREG is found in rat cerebral spinal 
fluid (CSF), plasma, hippocampus and cortex at concentrations (in ng/g) of 3, 1, 20 and 
17, respectively. Porcu et al. (2009), using GC-MS, found plasma levels of PREG to be 
0.3 ng/mL in rats while in humans the levels were determined to be 0.8ng/mL.  A study 
by Marx et al. (2006) using GC-MS found hippocampal levels of PREG at 3ng/g, slightly 
lower levels than that of Caruso et al. (2010). A determination of whole rat brain by 
Ebner et al. (2010) found PREG at concentrations of 1.7ng/g.  In contrast to PregS, 
PREG levels may be more consistent between human and rat brains. In a study by Marx 
et al. (2006) comparing the prefrontal cortex of cognitively intact subjects vs. subjects 
with AD, PREG concentrations (in ng/g) were 8.6 and 21, respectively.  
 Table 1 summarizes references quantifying the concentration of PREG and PregS 
in plasma and bulk tissue extracted from hippocampal (HIPP) and cortex (CTX).  The 
concentration of PREG and PregS in bulk tissue was converted to molarity using the 
assumption that 1 gram of tissue corresponds to 1 mL of solution in order to provide a 
basis of comparison for concentrations of steroids in solution. As noted below, this 
assumption and the preceding measurements of pg neurosteroid / mg of tissue ignores the 
heterogeneity of tissue and likely underestimates the concentration of steroids in vivo. 
PREG is lipid soluble and may remain in a subcellular fraction or aggregate in 
membranes following its conversion from cholesterol in the mitochondrial matrix. If 
PregS is produced intracellularly, its negative charge would limit diffusion across the cell 
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membrane, arguing against a homogenous distribution in bulk tissue.   The data 
summarized in Table 1 is not comprehensive, but instead, provides a survey of recent 
studies quantifying steroids in nervous tissue.  As the data would indicate (Table 1), there 
is an overall lack of consensus in the field of neurosteroid research as to the concentration 
of PregS in the central nervous system (Schumacher 2008).  Improvements in PregS 
tissue extraction and more sensitive quantification methods may be required before a 
definitive answer regarding PregS concentration in bulk tissue, subcellular fractions, and 
amounts released in response to stimuli can be determined.   
 The levels of PregS present in bulk brain tissue (low nanomolar range, Table 1) 
are consistent with the possibility that PregS could be concentrated in presynaptic 
terminals or glial cells and released at synapses (Gibbs 2006).  Consistent with a role for 
endogenous neurosteroids, previous studies have shown that blocking aromatase 
production of estradiol inhibits high frequency stimulation-induced LTP in rat vestibular 
brain slices (Grassi 2009).  PregS increases in EPSP frequency in rat CA1 pyramidal cells 
are NMDAR-dependent and can be eliminated using a PregS-specific antibody to 
scavenge extracellular PregS (Mameli 2005). Blocking P450scc activity inhibits LTP in 
rat dentate gyrus, which can be rescued by PREG, DHEA and DHEAS treatment of the 
slice at nanomolar concentrations (Tanaka 2012).  
 Barring a localized elevation in PregS via biotransformation or concentrated 
release sites there are a number of reports on the effects of PregS in the pM - nM range. 
PregS enhances binding of ifenprodil (an NMDAR antagonist) to rat cortical membranes 
with a maximal modulatory effect of 13nM (Johansson 2005). PregS inhibits GABA 
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sIPSCs with an IC50 of 26nM (Mtchedlishvili 2003). 100nM PregS enhances the 
NMDAR response via a G protein coupled receptor (GPCR) and increases NR1 
trafficking to the cell surface (Kostakis 2013), while 300nM PregS enhances LTP in 
hippocampal slices (Sliwinsky 2004). PregS at concentrations as low as 25pM stimulates 
[3H]DA release from striatal synaptosomes (Whittaker 2008), while 50nM PregS 
stimulates overflow of endogenous striatal dopamine release measured by in vivo 
microdialysis (Sadri-Vakili 2008).   
 
PregS as a candidate for development of novel cognitive enhancing NMDAR 
modulators 
 Whereas the role of PregS as an endogenous neuromodulator remains an open 
area for investigation, pharmacological evidence suggests that PregS may be a useful 
platform for development of novel high-affinity NMDAR positive modulators as 
cognitive enhancers. PregS is subtype-selective for NMDARs at micromolar 
concentrations (Malayev 2002).  We previously documented pM to nM NMDAR-
dependent effects of PregS on dopamine release in the striatum (Sadri-Vakili 2008; 
Whittaker 2008).  
 Results from our laboratory show that PregS modulates NMDAR receptor 
trafficking in oocytes and cortical neurons in culture in an NMDAR-contingent and Ca++-
dependent manner. These responses occur with greater potency than modulation of 
NMDAR 'fast' (msec) transmission and suggest a novel high potency PregS-induced 
stimulation of NDMAR trafficking (Kostakis et al., 2013).   Clearly, a PregS-like small 
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molecule cognitive enhancer would have great promise in the treatment of multiple 
neurological disorders such as Alzheimers disease (AD), depression and schizophrenia 
(with symptom components including cognitive dysfunction). 
 
PregS Modulation of Neurotransmitter Receptor Function 
GABAA receptors 
The GABAA receptor (GABAAR) is a member of a superfamily of ligand-gated ion 
channels, is the primary mediator of inhibitory synaptic transmission in the brain, and is 
modulated by compounds such as barbiturates, anesthetics and benzodiazepines (Rabow, 
1996). GABAARs are positively (PregS; Mienville 1989) and negatively (pregnan-
steroids; Crawley 1986) modulated by neuroactive steroids at distinct sites (Park-Chung 
1999). Studies suggest that neurosteroids act as endogenous GABAAR modulators with 
high potency (Belelli et al., 2005) highlighting the importance of structural determinants 
of neurosteroid activity at GABAARs in identifying novel GABAAR modulators.  A 
recent study demonstrated that 50µM PregS increases the apparent rate of desensitization 
of GABAA receptors; and, novel amino acids in the membrane spanning domain (M1) of 
the alpha subunit of the GABAA receptor have been found to specifically interact with 
potentiating neurosteroids such as allopregnanolone, (Akk 2008). Additionally, in these 
studies, PregS increases the off rate of GABA-site activation while 3,20(r/s)-pregnandiols 
(5a-pregnan-3b,20(S)-diol and 5b-pregnan-3b,20(S)-diol decreases the fast offset rate in a 
manner different than that of PregS in recombinant rat GABAA receptors ("1$2#2L)(Wang 
et al., 2008). Using chimeric receptors expressed in oocytes (Baker  2010) it was shown 
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that residues rendering C.elegans receptors insensitive to PregS actually increased 
sensitivity to PregS and 5!,3!-pregnane-3!,21-diol-20-one (THDOC) in human or rat 
GABAA receptors.  In addition, a potential endogenous role for PregS inhibition of 
spontaneously active !6"2# receptors expressed in developing cerebellar granule cells 
has been described (Baker 2010). These studies taken together provide further evidence 
that supports distinct binding sites for positive and negative neurosteroid modulation via 
the M1 domain.  
 Alternatively, dipricrylamine (DPA) a hydrophobic anion structurally unrelated to 
PregS exhibits many properties similar to PregS inhibition of GABAARs including 
concentration dependent inhibition, enhanced receptor desensitization, and sensitivity to 
the mutation of a residue in the receptor that abolishes inhibition by PregS and not 
picrotoxin (Chisari e2011).  It is thought that DPA and PregS may interact with 
GABAARs via a membrane-sensitive site rather than a traditional lock and key site on the 
oligomeric protein complex.  The abundance of structure-function studies of neurosteroid 
interactions with GABAARs lays the foundation for a structural model of neurosteroid 
modulation that can recapitulate the previous datasets and provide a platform to test 
hypotheses of neurosteroid binding and receptor gating. 
 In addition to direct modulation of GABAARs, neurosteroids also influence 
expression of other GABAAR modulators such as Acyl-CoA binding protein (ACBP). 
ACBP is proteolytically cleaved to peptides TTN and ODN (termed endozepines) that 
can bind to and reduce the affinity of GABAARs for GABA. These peptides also compete 
with benzodiazepine binding to GABAARs and to the peripheral benzodiazepine receptor 
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(PBR). Both ACBP and PBR are highly expressed in astrocytes but not neurons. 
Nanomolar concentrations of neurosteroids (cortisol, 5nM; PregS, 10nM; PREG, 50nM) 
induce the release of endozepines from mouse primary astrocytes within 5 min, 
indicating a non-genomic mechanism (Loomis 2010). The effect of cortisol was blocked 
by a PKA inhibitor, but was insensitive to brefeldin A blockade of secretion pathways  or 
pertussis toxin inhibition of downstream G-protein coupled receptor activity  (Loomis et 
al., 2010),  suggesting a secondary mode of action for indirect neurosteroid regulation of 
GABAAR signaling, and an additional potential therapeutic target for neurosteroid 
modulation of GABAARs. 
 
Glutamate receptors (NMDARs and AMPARs) 
 Excitatory transmission in the brain is primarily mediated by the ligand-gated 
glutamate receptor family consisting of NMDA, AMPA and kainate receptors. The 
NMDAR contains an obligatory NR1 subunit and one of four NR2 subunits (NR2A-D), 
and is under magnesium block during resting membrane potential. NMDARs are 
modulated by protons, zinc, and polyamines, and regulated by phosphorylation of amino 
acid residues and the reduction/oxidation (redox) state of the cell (Dingledine 1999). 
PregS modulation of NMDARs is subtype specific; PregS potentiates the response of 
NMDARs containing NR2A and NR2B subunits, and inhibits the response of receptors 
containing NR2C and NR2D subunits (Malayev 2002). Similar to GABAAR modulation, 
positive and negative modulation by neuroactive steroids occurs at distinct sites on the 
NMDAR (Park-Chung 1997). It is known that a steroid modulatory domain in the fourth 
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transmembrane region of the NMDAR NR2B subunit mediates potentiation by PregS 
(Jang 2004). Further mutagenesis studies and high resolution X-ray crystallogarphy 
would further refine a model of the PregS binding site and provide a molecular target for 
regulation of NMDARs.     
 In order to model PregS binding to NMDARs and AMPARs, Cameron et al., 
2012 expressed and purified the NMDAR GluN2B and AMPAR GluA2B domains. 
PregS binding to S1S2 region on GluN2B and the amino terminal domain of GluA2B 
was demonstrated using fluorescence spectroscopy (which relies on detection of 
alterations in the chemical environment of tryptophan residues) (Cameron 2012). PregS 
binding to the AMPAR ATD is a novel finding, and supports allosteric modulation by 
PregS to both AMPAR and NMDAR signaling (Cameron 2012).  Interestingly, structure-
activity studies show that PregS modulation of NR1/NR2A containing receptors has a 
pH-dependent and independent component.  PregS potentiation of NMDA-induced 
currents in oocytes expressing these receptors is reduced at high pH where tonic proton 
inhibition of the receptor is negligible (Kostakis 2011).  Introducing a point mutation 
known to decrease proton sensitivity of NR2A-containing NMDARs does not affect 
PregS potentiation dependence on pH, while addition of an NR1 amino acid exon-5 insert 
enhances sensitivity to both proton inhibition and potentiation by PregS. In contrast, 
PregS modulation of NMDARs containing NR2B is minimally sensitive to proton 
inhibition and is not affected by the exon-5 insert (Kostakis 2011). PregS potentiation of 
NMDA induced currents is diminished following membrane patch excision and by kinase 
inhibitors staurosporine (serine/threonine kinase inhibitor) and H89 (PKA inhibitor), 
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indicating that PregS modulation of NMDARs is also phosphorylation state-dependent 
(Petrovic 2009).  
 In order to determine the affinity of PregS for NMDARs containing NR2B 
Johansson et al., 2008 studied PregS displacement of [3H]ifenprodil from membranes 
derived from CHO-E2 cells expressing NR1/NR2B (under the control of a heat-sensitive 
promoter). PregS increases [3H]ifenprodil specific binding to the membranes in a bell-
shaped curve with a peak at 1nM PregS, while pregnanolone sulfate (PAS) decreases 
specific binding in a similar manner with maximal inhibition at 10nM concentrations. 
The modulatory effects of PregS but not PAS on ifenprodil binding were sensitive to 
glutamate, indicating separate binding sites for the neurosteroids on NR2B-containing 
NMDARs. Moreover, results of a functional calcium assay show that PregS enhances the 
inhibitory effect of ifenprodil on glutamate induced calcium influx, while PAS has the 
opposite effect (Johansson 2008). These results were supported in a companion study in 
which nanomolar concentrations of PregS and PAS (0.1nM and 1nM, respectively) shifts 
[3H]-MK-801 binding to rat hippocampal membranes by ifenprodil from one-site to two-
site displacement, indicating that these neurosteroids may allosterically modulate NR2B-
containing NMDARs to reveal a high affinity binding site of the ion pore in the presence 
of ifenprodil (Elfverson 2008).  Long term treatment of rats with morphine results in an 
increase in specific binding of [3H]ifenprodil in frontal cortex and not the hippocampus or 
hypothalamus, suggesting a biologically relevant specific upregulation of NR2B that may 
occur in disorders of brain function (Johansson 2010). The effects of PregS and DHEAS 
on [3H]ifenprodil binding to membrane homogenates were unaffected by morphine 
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treatment, while the PAS binding profile in cortex was altered, suggesting a change in 
NR2B receptors affecting PAS but not PregS or DHEAS allosteric modulation of the 
receptor (Johansson 2010). 
 
TRP Channels 
 It was recently discovered that PregS is an agonist at transient receptor potential 
melastitin 3 (TRPM3) channels (Wagner 2008). TRPM3 channels are highly expressed in 
the brain (Lee 2003; Fonfria 2006; Hoffman 2010) and are novel targets mediating PregS 
modulation of CNS function (Harteneck 2013). TRPM3 channels are more permeable to 
cations than monovalent anions, and PregS has been shown to stimulate entry of zinc 
through the TRPM3 channels in mouse pancreatic beta islet cells (Wagner 2010). PREG 
and epipregnanolone sulfate stimulate TRPM3 channels, but do not stimulate Ca2+ 
increases to as great an extent as PregS, while PAS was weaker than epipregnanolone 
sulfate, and corticosterone 21-sulfate had no effect, indicating that the unsaturated A-ring 
and location of the sulfate group are important for TRPM3 agonism. Additionally, 
DHEAS was weaker than PregS, while DHEA was weaker than DHEAS, indicating that 
the acetyl group at C21 is also a determinant in structure-activity at TRPM3 (Majeed 
2010).  Progesterone (10nM - 10µM) but not allopregnanolone inhibits PregS induced 
Ca2+ influx in HEK293 cells constituitively expressing TRPM3.  The effect of 
progesterone on these channels is independent of agonist, as progesterone inhibited Ca2+ 
currents following a solution change from a Ca2+-free to 5mM Ca2+ solution.  Binding of 
progesterone, PregS, dihydrotestosterone, cortisol, and nifedipine to TRPM3 was 
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demonstrated using application of cell lysates with GFP-labeled TRPM3 to membranes 
spotted with steroids or chemical compounds (Majeed 2012). It was also recently 
discovered that TRPC5 channels are negatively modulated by PregS, PA, PAS, 
progesterone and dihydrotestosterone, while DHEAS and 17b-estradiol had weak effects, 
with no effect of PREG and allopregnanolone (Majeed 2011).  Together, the results 
indicate the existence of a unique binding site mediating PregS activation of TRPM3 
channels. 
 Functionally, TRPM3 channels are required for PregS induced up-regulation of c-
Jun, c-Fos promoter activity and transcription of a CRE-regulated reporter gene in an 
insulinoma cell line and in primary cultured mouse pancreatic "-cell islets (Muller 2011).  
PregS induces Ca2+ increases in fibroblast-like synoviocyte (FLS) primary cells derived 
from patients with rheumatoid arthritis and inhibited secretion of hyaluronan (Ciurtin 
2010). PregS activation of TRPM3 in human vascular smooth muscle cells (VSMCs) 
results in increased intracellular Ca2+ and disinhibition of IL-6 and hyaluronan secretion, 
while PregS induced contractile responses in mouse aorta were inhibited by a TRPM3 
inhibitor but insensitive to voltage-gated Ca++ channel inhibition (Naylor 2010). 
 
Sigma receptors  
 Previous studies in the literature also suggest that there is a role for sigma ($) 
receptor-mediated neurosteroid action (Sabeti et al., 2008; Mtchedlishvili et al., 2010; 
Yang et al., 2012). Nandrolone, an anabolic steroid that increases aggressive behavior 
and down-regulates NR2B-containing NMDARs, is hypothesized to modulate PregS 
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targets including the NMDAR and $R (Elfverson 2011).  Chronic treatment of rats with 
nandrolone decreases high affinity binding of neurosteroids PregS, PAS and DHEAS in 
the presence of ifenprodil to rat brain extracts (Elfverson 2011).  However, the treatment 
did not alter neurosteroid binding to NR2B-containing NMDARs, suggesting a selective 
down-regulation of $Rs (Elfverson 2011).  It has also been reported that pregnenolone 
(10mg/kg) increases $1R immunoreactivity in rat retina and decreases intraoccular 
pressure in a rat model of ocular hypertension (Sun 2012).  
 
Voltage-gated channels 
 Neurosteroid-specific responses have also been reported for members of a 
subfamily of inwardly rectifying K+ channel (Kir). The Kir2.3 channel, which is 
expressed in mammalian forebrain, is potentiated by PregS but not other neurosteroids 
including PREG, DHEA, DHEAS, progesterone, allopregnanolone or THDOC.  PregS 
potentiation of Kir2.3 has an EC50 of 16 µM, and is selective for Kir2.3 channels (Kir 1.1, 
2.1, 2.2 and 3.1/3.2 channels were also tested) (Kobayashi 2009).  These results indicate 
that at µM concentrations, PregS may induce hyperpolarization in cells expressing the 
Kir2.3 channel. Blockade of L-type voltage gated Ca2+ channels by verapamil inhibits 
PregS induced upregulation of a CRE-reporter gene in pancreatic beta islet cells, while 
PregS is inactive in a cell line that expresses L-type voltage gated Ca2+ channels and not 
TRPM3 (Muller 2011).  PregS, and with lower potency, DHEA and DHEAS (but not 
PREG) decreases current through Nav1.2, a voltage-gated sodium channel (Horishita et 
al., 2012). 
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Taken together, PregS modulation of neurotransmitter receptor function highlights the 
need for structure-function studies of PregS-specific interactions at GABAARs and 
NMDARs.  PregS modulation of  GABAARs, NMDARs, TRP and voltage-gated 
channels may provide novel targets for neurosteroid-based therapeutics.  PregS 
modulation of neurotransmitter receptor function determines the role PregS plays in 
regulation of neuronal function. Further elucidation of PregS targets and its mechanism 
of action at the molecular level will lead to a better understanding of PregS modulation of 
synaptic activity.  
 
PregS and Synaptic Activity 
Glutamatergic Transmission 
 PregS increases the frequency (with no effect on amplitude) of glutamatergic 
spontaneous EPSCs with an EC50 of 65µM in mechanically isolated rat hippocampal hilar 
neurons with intact proximal dendrites and cell-free presynaptic nerve terminals (Lee 
2010)  The effect of PregS is dependent on external Ca2+ and blocked by an intracellular 
Ca2+ chelator, reduced by CPA (a sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
(SERCA) antagonist),  and blocked by non-specific TRP channel blockers. The effect of 
PregS is not blocked by (target in parentheses) D-AP5 (NMDAR), BD1063 ($1R), MLA 
(!7 nicotinic receptor), TTX (voltage dependent Na+ channel), Sq22536 (adenyly 
cyclase) or KT5720 (PKA) (Lee 2010). 
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 Evidence supporting TRPM3 modulation of glutamatergic synaptic activity is 
provided by a study demonstrating that mefenamic acid, used to block TRPM3 channels, 
inhibits PregS (25µM)-induced increases in AMPA-mEPSC frequency (Zamudio-
Bulcock et al., 2011b). TRPM3 channels are expressed in the developing rat cerebellar 
cortex and TRPM3-like channels are expressed at glutamatergic synapses in neonatal 
purkinje cells.  PregS (2.5µM), epipregnanolone sulfate (25µM) and nifedipine (which 
acts as an agonist at TRPM3 channels) were also sufficient to induce an increase in 
mEPSC frequency. Progesterone, which does not activate TRPM3 channels, does not 
increases mEPSC frequency (Zamudio-Bulcock et al., 2011b). 
 It has been reported that PregS (µM concentrations) induces an increase in AMPA 
receptor-mediated mEPSC frequency (which is blocked by the AMPAR antagonist GYK 
53655) and, to a lesser extent, increases in GABAA receptor-mediated miniature 
postsynaptic currents in acute rat cerebellar slices. The effect of PregS on mEPSC 
frequency is more robust in P4-10 rats than P12 rats, and is not blocked by antagonists 
targeting NMDA, glycine, voltage gated Ca2+ channels, $1 or !7nACh receptors. Bath 
application of a membrane permeable Ca2+ chelator blocks the PregS effect on mEPSC, 
while dialysing the chelator via patch pipet has no effect on PregS potentiation, 
supporting the conclusion that PregS effects occur via presynaptic action. Finally, 
lanthanide3+ (La3+), a non-selective TRP channel blocker, eliminates the PregS effect 
(Zamudion-Bulcock et al., 2011a), further supporting TRPM3 as a target for PregS 
inducing glutamate release. Although it remains to be demonstrated, an interesting model 
that accounts for the most consistent observations in the literature is outlined in 
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Valenzuela et al. (2008), in which PregS induces presynaptic Ca2+ influx that increases 
presynaptic glutamate release and promotes insertion of AMPARs to the postsynaptic 
membrane, thereby activating silent synapses.  
 Activation of glutamatergic signaling may also feedback on neurosteroid 
production. Incubation of rat C6 glioma cells with high concentrations of glutamate 
(1mM) and prevention of AMPA receptor desensitization results in attenuation of 
sulfotransferase 2B (SULT2B1a) RNA expression, is inhibited by an AMPAR antagonist 
and attenuated by a neuronal nitric oxide synthase (nNOS) inhibitor.  Nitric oxide (NO) 
donors also attenuate SULT2B1a RNA expression, suggesting that activation of 
AMPARs could lead to inhibition of SULT2B1a expression via an NO mediated pathway 
(Kohjitani 2008). 
 
Synaptic potentiation 
 5µM PregS potentiates LTP at hippocampal CA1 synapses following 100Hz 
stimulation. In the same model, D-AP5 blocks LTP induction which is rescued with 
PregS + D-AP5. In chronic intermittent ethanol (CIE) treated rats, however, PregS + D-
AP5 does not induce LTP following100Hz stimulation. As CIE treated rats exhibit a D-
AP5 independent form of LTP, the LTP potentiated by PregS may be occluded by CIE 
treatment (Sabeti 2008).  In the medial prefrontal cortex (mPFC) PregS inhibits LTP in a 
manner that depends on an !2-adrenoreceptor, Gi protein-coupled, adenylate cyclase 
(AC) to PKA signaling pathway (Wang 2008).  PregS also induces a leftward shift in a 
hippocampal LTP/LTD frequency curve (Chen et al., 2009).  This study used a voltage-
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sensitive dye to measure changes in EPSP slope and amplitude following stimuli of 
varying frequency in rat hippocampal slice granule cells.  Maximal PregS potentiation of 
LTP occurs  ~20Hz and correlates with increased ERK phosphorylation. The effect also 
requires L-type voltage gated Ca2+ channel activation, but is insensitive to NMDAR 
inhibition by D-AP5 or $R block by NE100 (Chen 2009). 
 In the hippocampal trisynaptic pathway (dentate gyrus, CA3, CA1) the change in 
population spike amplitude is stimulation frequency-dependent. Over a stimulation 
frequency range of 2-77Hz the dentate field acts as a low-pass filter, while the CA3 and 
CA1 fields act as a bandpass filter (with CA1 having a narrower range than CA3). 1µM 
PregS has no effect on dentate filtering properties, while it increases the gain (population 
spike amplitude at select stimulation frequencies) in the CA3 (%, 4-8Hz range) and CA1 
(g, 30-100Hz range), supporting a role for PregS in modulating hippocampal filtering 
properties (Scullin 2012).  
 
Nitric Oxide-cyclic GMP 
In vivo microdialysis studies in rat cerebellum demonstrate that THDOC (100nM) does 
not affect basal levels of cGMP but reduces NMDA activation of cGMP. Pregnanolone at 
higher concentrations (10µM) reduces extracellular cGMP and eliminates NMDA-
induced cGMP. PregS (100nM) increases basal cGMP and potentiates NMDA induced 
cGMP for a sub-maximal dose of NMDA, while PREG is inactive. DHEAS (100nM) 
induces a slight increase in cGMP and completely inhibits NMDA effects on cGMP. 
Allopregnanolone also increases basal levels of cGMP and blocks NMDA-induced 
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cGMP. Using citrulline as an indicator of NOS activity, the effects of neurosteroids tested 
on NOS activity were identical to their effects on cGMP levels (Cauli 2011). However, it 
is difficult to determine the contribution of GABA or NMDA receptor modulation in the 
neurosteroid responses as no inhibitors were tested in the study.   
 Hyperammonia is a pathological condition that impairs the glutamate-NO-cGMP 
pathway, likely as a result from tonic activation of GABA and NMDA receptors. 
Hyperammonia potentiates the effects of the GABAAR positive modulators THDOC and 
PA on inhibition of cGMP and NMDA-induced cGMP. Similarly, PregS potency in 
potentiation of NMDA-induced cGMP was further increased in rats with hyperammonia,. 
While in controls PREG is inactive, in conditions of hyperammonia, PREG completely 
inhibits NMDA-induced increases in cGMP (Gonzalez-Usano 2013).  
 
Glycinergic transmission 
 PregS increases the frequency and decreases the amplitude of IPSCs (blocked by 
strychnine, a glycine receptor antagonist) in rat medullary dorsal horn neurons with an 
EC50 of 162µM, suggesting an increase in presynaptic glycine release and inhibition of 
postsynaptic glycine receptors. Concentrations of PregS as low as 10µM decreased 
postsynaptic glycine-induced membrane currents but did not affect the EC50 value for 
glycine. The PregS effect on IPSCs was Ca2+ dependent, blocked by non-specific TRP 
channel blockers, but independent of NMDA, $1 and !7 nicotinic receptors (Hong 
2013). 
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Dopamine 
 The diverse and selective effects of PregS on neuronal function continues into the 
regulation of dopaminergic transmission where PregS (25pM, 25nM and 50!M) has been 
shown to induce DA (and not GABA or glutamate) release from rat striatal nerve 
terminals.  Dopamine release induced by 25nM PregS is blocked by D-AP5 (NMDARs) 
but not by CNQX (AMPAR antagonist) or a mixture of antagonists (receptors blocked: 
GABAAR, 5-HT3R, nAchR, D1R, D2R, and AMPA/KaR). PREG has no effect on DA 
release in the same assay (Whittaker 2008) suggesting that sulfation is required for the 
response.  The effect of PregS on dopamine release from terminals ex vivo is supported 
by an in vivo microdialysis study in which PregS (10, 25, 50nM) and a synthetic 
structural analog to PregS, pregnenolone hemisuccinate (PHS, 50nM and 300nM) 
increase rat striatal DA levels. The concentration-effect curve for PregS induced DA is 
bell shaped, in that 5nM, 300nM and 100!M PregS are without effect. 50nM PregS 
induced DA release is blocked by D-AP5, but not by the $1R antagonist  BD1063 (while 
PREG, PA and progesterone are without effect on striatal DA levels) (Sadri-Vakili et al., 
2008).   
 
 Overall, PregS has an excitatory effect on neurotransmission including an 
increase in glutamate, glycine and dopamine release, potentiation of the NMDAR, 
NMDA-induced cGMP production, and potentiation of LTP. However, the effect of 
PregS on synaptic transmission is not always clear-cut. For instance, in rat hippocampus 
PregS potentiates LTP (Sebeti 2008) while in the rat mPFC PregS inhibits LTP (Wang 
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2008).  Not surprisingly, the effect of PregS on behavioral tests of memory is also 
complex, as the PregS effects  of PregS seems to depend on the experimental measure of 
memory as well as the site of PregS injection (see for example; Petit 2011 vs. Nanfaro 
2010).  The existence of multiple pre and post synaptic targets of PregS at a given 
synapse would complicate the overall effect of PregS on synaptic transmission. 
Therefore, any working model of the effect of PregS on a given synapse would have to 
take into account multiple potential sites of action for PregS, each with unique affinity 
and maximal effect contributing to the overall response that PregS would have on 
synaptic function.  
 Additional complexity resulting from neural network effects of PregS on different 
neuronal pathways may reduce the predictive value of therapeutic design based on its 
modulation of a given target, necessitating preclinical and clinical studies that verify the 
concentration-dependent effects of PregS on complicated biological functions. Recent 
results of preclinical cell based models and behavioral tests are consistent with PregS 
potentiation of the NMDAR and excitatory neurotransmission that may provide valuable 
insight into the role of PregS in neuronal function and its potential use in the 
development of novel therapeutics.  
 
PregS in Therapeutics and Disease 
Cell culture / Animal models 
 At a concentration of 500nM, PREG protects against 20mM A" peptide toxicity 
after 72 hr exposure in PC12 cells. In the same assay, 500nM PregS has no protective 
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effect on cell death but decreases cell viability during A"-exposure. At higher 
concentrations, both 50µM PREG and PregS potentiate A"-induced toxicity over a 72 hr 
treatment (Akan 2009).  In contrast, PregS has been shown to enhance the survival of 
dentate gyrus (DG) cells and to potentiate EPSPs in the dentate gyrus of mouse 
hippocampal slices (Yang 2012).  Treatment with PregS (20mg/kg subcutaneously) 
rescues deficits in spatial memory performance and cell death caused by a single (i.c.v.) 
injection of aggregated Ab(25-35) (3 nmol/mouse), an effect which is mediated by $1Rs, !7 
nAChRs, and correlates with changes in phosphorylated ERK (Yang 2012). Sustained 
(60 min post-PregS) increases in EPSPs are blocked by !7nAChR, $1R and NMDAR 
antagonists, however only NMDAR antagonists are capable of reversing the PregS effect. 
PregS injections that enhance survival of DG neurons are also blocked by the NMDAR 
antagonist D-AP5 (Yang et al., 2010), consistent with a role for the NMDAR in PregS-
induced neuroprotection.  
 Yet, behavioral studies that examine the effects of PregS on measures of learning 
memory, yield mixed results. PregS and its synthetic enantiomer (ent-PregS) injected into 
the lateral ventricle in mice have promnestic effects.  Surprisingly, the PregS effect, but 
not ent-PregS, is sensitive to forebrain NR1 knockout (Petit et al., 2011), again 
suggesting that the NMDAR is the target for PregS memory enhancement.  In contrast, 
PregS (5ng) injected bilaterally into the hippocampal CA1 area of rats immediately after 
a passive avoidance training session impairs 24 hr passive avoidance retention where 
allopregnanolone has no effect (Martin-Garcia 2008a).  A concentration-dependent effect 
of PregS has also been reported where its injection at 1.2µM into the lateral septum 
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impairs novel object recognition while 0.12 and 12µM PregS (and PREG) have no effect 
(Nanfaro 2010). 
 Bilateral intrahippocampal CA1 infusions of allopregnanolone (AlloP) at 0.2mg 
were chosen for use in studies of locomotion and anxiety based on previous evidence 
showing that systemic subcutaneous administration of 8mg/kg of allopregnanolone 
results in cortical levels of AlloP in the concentration range (0.4mg/g) causing anxiolytic 
effects.  Doses of PregS were then chosen such that 5ng of PregS diluted in a 0.5µL 
infusion volume results in 24µM PregS- in the range of known PregS modulation of 
GABAA and NMDA receptors.  PregS does not affect prepulse inhibition (PPI), while 
AlloP enhances PPI startle inhibition. The same CA1 infusions of AlloP (0.2mg) or 
PregS (5ng) decrease locomotor activity. Neonatal exposure to AlloP potentiates 
intrahippocampal PregS-induced decreases in locomotor activity, suggesting a possible 
increase in the GABAAR response to neurosteroids. However, neonatal exposure to AlloP 
or finasteride (5a-reductase inhibitor) has no effect on subsequent PregS or AlloP 
modulation of open field behavior, a measure of anxiety (Darba 2011). The effects of 
PregS and AlloP would be expected based on their respective activity at NMDARs and 
GABAARs, and indicate that predictions of PregS effects on behavior may, with restraint, 
be made based on its effects on ion channels.  
 In the mouse tail suspension test (TST), used as an animal model of depression, 
40mg/kg subcutaneous PregS and 10 and 40mg/kg (but not 20mg/kg) DHEAS decreases 
immobility time, responses which are blocked by pretreatment with putative $1R 
antagonists BD1047, progesterone and rimcazole (Dhir et al., 2008).  The 3"-
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hydroxysteroid dehydrogenase (3"-HSD) inhibitor trilostane would be expected to halt 
conversion of pregnenolone to progesterone and 17-OH pregnenolone to 17-OH 
progesterone. Trilostane has antidepressant-like properties in that it decreases immobility 
time in a forced swim test in mice and is equally active in control and stressed mice.  
Trilostane also has anxiolytic effects in behavioral tests although the dose-response is bell 
shaped, indicating a narrow window of efficacious concentrations (Espallergues 2009).  
The effects of "-HSD inhibition on specific neurosteroid concentrations in the brain are 
unknown, making it difficult to correlate the behavioral effects with changes in 
neurosteroid levels.  Neonatal administration of finasteride has an anxiogenic effect in 
adult rats that is not rescued by hippocampal CA1 infusion of AlloP but exacerbated by 
hippocampal PregS (Martin-Garcia 2008b).  Allopregnanolone has anxiolytic effects 
when administered bilaterally in the hippocampal CA1 region.  While PregS has no effect 
on behavioral measures of anxiety, it impaired performance in a behavioral measures of 
memory (Modol 2011).   
 In summary, PregS has NMDAR-dependent promnestic and neuroprotective 
effects.  However, the promnestic effect of PregS likely depends on the mode of 
administration and behavioral model being tested (for example, see Modol 2011). The 
promnestic effect of PregS in parallel to a neuroprotective effect in the presence of 
A" toxicity, as assayed in culture, suggests that PregS may be a potential therapeutic in 
AD, however no recent clinical trials have been completed to date using PregS as an 
adjunct therapeutic in the disease.  The PregS-induced reduction of depression-like 
symptoms in mice may also carry over into the clinic, as indicated below.  Additionally, 
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several promising clinical trials indicate a potential role for the PregS precursor PREG in 
ameliorating symptoms of schizophrenia, as well as a correlation between serum PregS as 
a biomarker for treatments for alcohol addiction and epilepsy.  
 
Humans 
 Two recent clinical trials investigated the effect of medications for alcohol 
dependency or epilepsy on serum levels of neuroactive steroids. In one study focusing on 
the hypothalamic-pituitary-adrenal axis (HPA), PregS serum levels are responsive to 
HPA hormone levels. Deoxycorticosterone levels are increased by naloxone therapy in 
alcohol-dependent patients, while ovine corticotropin releasing hormone (oCRH)-induced 
deoxycorticosterone levels are blunted in alcohol dependent patients, and decrease 
following treatment with dexamethasone. PregS serum levels are increased by 
cosyntrophin and decreased by dexamethasone but unaffected by naloxone or oCRH 
(Porcu 2008). In a study on 28 female patients with epilepsy, treatment with 
carbamazepine or primidone decrease serum levels of DHEAS in patients in the follicular 
and luteal phase of menstruation, while levels of PregS are decreased by carbemazepine 
in the luteal phase (Hill 2010).   
 Levels of circulating steroid hormones are predictive of schizophrenia symptoms, 
as indicated in a study of 13 male patients with schizophrenia (22 control subjects) and 
18 female patients with schizophrenia (25 control subjects) (Bicikova 2013).  In support 
of the potential for a therapeutic application of neurosteroids in schizophrenia, a clinical 
trial demonstrated that pregnenolone reduces negative symptoms in patients with 
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schizophrenia, while increasing serum levels of PREG, PregS, allopregnanolone, DHEAS 
and progesterone (Marx 2009).  More recently, it was demonstrated that an 8-week dose 
of PREG reduces positive symptoms of schizophrenia and improves memory and 
attention in patients concurrently taking antipsychotic medication (Ritsner 2010). In a 
clinical trial comparing PREG to placebo (19 PREG subjects, 18 placebo subjects), 
PREG supplementation results in a significantly greater decrease in depressive symptoms 
in patients with mono- and bipolar depression with a history of substance abuse (Osuji 
2010). One critical limitation to these studies is the small sample size, while encouraging, 
larger clinical trials are needed to verify the efficacy of adjunctive PREG or PregS in 
schizophrenia.  
 
Conclusions  
 Neurological disorders such as Alzheimer's disease, depression and schizophrenia 
have component symptoms associated with deficits in learning and memory (Lee 2009). 
There is currently an unmet medical need for cognitive enhancers with efficacy across the 
spectrum of neurological disorders associated with learning and memory impairment. 
NMDAR antagonists reproduce symptoms resembling schizophrenia in humans (Gaspar 
2009), while positive modulation of NMDARs is considered to be a potential mechanism 
for cognitive enhancer action/discovery (Bibb 2010). Negative symptoms of 
schizophrenia such as cognitive deficits are currently not managed by antipsychotic 
treatments and are correlated with poor clinical outcomes (Milev 2005).  Similarly, 
glutamatergic dysfunction in depression is an active area of research, and the NMDAR is 
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a validated therapeutic target (Pilc 2013).  Recent research on the effects of PregS on the 
molecular, synaptic, and behavioral level all indicate that PregS is a promising candidate 
as a cognitive enhancer.  Novel structure-function studies may result in the design of a 
PregS-based molecule specific for the NMDAR, while within the last 5 years novel PregS 
targets such as the TRPM3 channel and the Kir2.3 channel have been discovered. 
Additionally, the excitatory effect of PregS on synaptic function is consistent with the 
potential for cognitive enhancement including potentiation of glutamatergic signaling and 
long-term synaptic potentiation.  Preclinical results such as neuroprotection from A" 
toxicity and the promnestic effect of PregS, in balance with clinical results, are 
promising.  Moreover, the efficacy of the PregS precursor PREG in two clinical trials for 
schizophrenia and one for depression strongly suggest that further development of PregS, 
and related small molecules, as a cognitive enhancer will be a valuable avenue of 
investigation.  
 
Respective contribution 
Written by C. Smith in collaboration with Dr. D.H. Farb. 
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Chapter 2 
Pregnenolone Sulfate Stimulates Trafficking of Functional NMDA Receptors to the 
Cell Surface via a Non-Canonical G-Protein and Ca2+ Dependent Mechanism2 
 
  
Abstract 
NMDARs mediate fast excitatory synaptic transmission and play a critical role in 
synaptic plasticity associated with learning and memory. NMDAR hypoactivity has been 
implicated in the pathophysiology of schizophrenia, and clinical studies reveal reduced 
negative symptoms of schizophrenia with a dose of pregnenolone that elevates serum 
levels of the neuroactive steroid PregS. This report describes a novel process of delayed 
onset potentiation whereby PregS approximately doubles the cell’s response to NMDA 
via a mechanism that is pharmacologically and kinetically distinct from rapid positive 
allosteric modulation by PregS.  The number of functional cell surface NMDARs in 
cortical neurons increases 60 -100% within 10 min of exposure to PregS as shown by 
surface biotinylation and affinity purification. Delayed onset potentiation is reversible 
and selective for expressed receptors containing the NR2A or NR2B, but not NR2C or 
NR2D, subunits.  Moreover, substitution of NR2B J-K helices and M4 domain with the 
corresponding region of NR2D ablates rapid allosteric potentiation of the NMDA 
response by PregS but not delayed onset potentiation. This demonstrates that the initial 
phase of rapid positive allosteric modulation is not a first step in NMDAR upregulation. 
Delayed onset potentiation by PregS occurs via a non-canonical, pertussis toxin sensitive 
                                                
2 Kostakis, E*, Smith, C*, Jang, MK, Martin, SC, Richards, KG, Russek, SJ, Gibbs, TT, Farb, DH (2013) 
Molecular Pharmacology 84:261-74. *Co-first authors 
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G-protein coupled and Ca2+ dependent mechanism that is independent of NMDAR ion 
channel activation. Further investigation into the sequelae for PregS stimulated 
trafficking of NMDARs to the neuronal cell surface may uncover a new target for the 
pharmacological treatment of disorders in which NMDAR hypofunction has been 
implicated. 
 
Introduction  
NMDARs play a critical role in synaptic plasticity underlying learning and memory, in 
part by dynamically regulating the trafficking of AMPA receptors via NMDAR channel 
mediated Ca2+ transport into dendritic spines. NMDA receptor trafficking is also 
regulated in response to neuronal activity, via both phosphorylation-dependent and 
phosphorylation-independent pathways (Chen and Roche, 2007; Lau 2009). 
NMDAR antagonists reproduce both the positive and negative symptoms of 
schizophrenia in humans and worsen the symptoms of nonmedicated patients  (Gaspar 
2009), suggesting that NMDAR hypofunction contributes to the symptoms of 
schizophrenia. Consistent with this hypothesis, enhancing NMDAR function by 
administering agonists acting at the NMDAR glycine site has been reported to be 
effective in reducing symptoms of schizophrenia  (Labrie and Roder, 2009). The negative 
symptoms of schizophrenia, including cognitive deficits, blunted affect, poverty of 
speech, anhedonia, asociality, and lack of motivation, are highly predictive of poor 
clinical outcome  (Milev 2005), and are largely refractory to conventional 
antidopaminergic pharmacotherapy. Pharmacological options for enhancing NMDAR 
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function are currently limited to acute agonism of receptor activity.  
The results of clinical trials indicate that the positive and negative symptoms of 
schizophrenia are ameliorated in patients receiving adjunctive treatment with 
pregnenolone  (Marx 2011), concordant with elevated serum levels of the neuroactive 
steroid PregS  (Marx 2009). PregS enhances learning and memory in animal models  
(Gibbs 2006; Marx 2011) and enhances LTP at hippocampal CA1 synapses  (Chen 2007; 
Sabeti 2007; Sliwinski 2004). PregS at micromolar concentrations acts as an allosteric 
modulator for a variety of neurotransmitter receptors, including glutamate, glycine, and 
GABAA receptors  (Wu 1991; Majewska and Schwartz, 1987). In particular, PregS 
enhances activation of NMDARs containing NR2A (NR1/2A receptors) or NR2B 
(NR1/2B receptors), while inhibiting receptors containing NR2C (NR1/2C receptors) or 
NR2D (NR1/2D receptors)  (Wu 1991). Rapid enhancement of NMDAR function by 
PregS is evident on a time scale of seconds, consistent with direct allosteric modulation 
of cell surface NMDARs  (Park-Chung 1997; Wu 1991). Analysis of recombinant 
NMDAR chimeras expressed in Xenopus laevis oocytes (henceforth, oocytes) has 
identified a steroid modulatory domain and possible PregS binding site on the NR2 
subunit that includes the J/K helices in the S2 region of the glutamate recognition site and 
the contiguous fourth membrane domain  (Jang 2004).  While exploring the effects of 
PregS in vivo, we found a higher potency process whereby low nM sulfated steroid 
released DA from striatal synaptosomes  (Whittaker 2008) ex vivo and the striatum in 
vivo contingent upon NMDAR activity  (Sadri-Vakili 2008). However, the cellular 
mechanism by which PregS may act at high potency is unknown.   
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 This report shows that PregS pharmacologically stimulates NMDA efficacy by 
enhancing receptor trafficking to the cell surface.  This occurs via a novel target and 
pathway that is dependent upon intracellular Ca2+ signaling but not NMDAR channel 
activation or entry of extracellular Ca2+. Instead, PregS stimulates release of intracellular 
Ca2+ via a pertussis toxin (PTx) sensitive and phospholipase C (PLC) dependent pathway. 
Therefore, in addition to ionotropic signaling, NMDARs are capable of regulating their 
own surface expression through a non-canonical mode of signaling  (Rozas 2003) that 
utilizes an intracellular transduction pathway more typical of GPCRs.   
 
Materials and Methods 
Materials. Rat NR1-1a (hereafter referred to as NR1) cDNAs  were provided by Dr. S. 
Nakanishi and the cDNAs of NR2A, NR2B, NR2C, and NR2D subunits were gifts from 
Dr. P.H. Seeburg.  Stock solutions of steroids were prepared in dimethyl sulfoxide 
(DMSO). Final concentration of DMSO in all buffer and drug solutions was 0.5%. 
Chemicals were from Sigma Chemical (St. Louis, Missouri). Restriction enzymes were 
from New England Biolabs (Beverly, Massachusetts). 
Preparation of cRNA. Plasmids were linearized with appropriate restriction enzymes 
prior to in vitro transcription using mMESSAGE mMACHINE™ High Yield Capped 
RNA Transcription kits (Ambion, Inc., Austin, TX). Plasmids containing NMDAR 
subunits were linearized with NotI (NR1), KpnI (NR2B), or XhoI (NR2A). Linearized 
DNAs were subjected to phenol/CHCl3 extraction and ethanol precipitation. The T7 in-
vitro transcription kit was used for NR1 and NR2A cRNAs and the SP6 kit was used for 
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NR2B cRNAs. 
Receptor expression in oocytes. Expression of NMDA and GABAA receptors in oocytes 
was carried out as previously described  (Kostakis et al., 2011; Berezhnoy et al., 2008). 
Briefly, oocytes from Xenopus laevis frogs (Nasco, Fort Atkinson, Wisconsin) were 
micro-injected with cRNAs transcribed in-vitro from plasmids containing cDNAs of 
desired NMDAR or GABAA receptor subunits, and maintained in Barth’s solution (in 
mM): (84 NaCl, 2.4 NaHCO3, 0.82 MgSO4, 1 KCl, 0.33 Ca(NO3)2, 0.41 CaCl2, 7.5 
Tris/HCl,  2.5 pyruvate, 100 U/ml penicillin/streptomycin, pH 7.4) at 18°C for 2 - 4 days 
before recording.  
Oocyte electrophysiology. Two-electrode voltage clamp recordings from oocytes were 
conducted (23 - 25°C; holding potential -70 mV) and membrane currents filtered (1 kHz) 
and digitized and sampled (100 Hz) as described previously  (Malayev et al., 2002). 
Ca2+and Mg2+ free Ba-Ringer perfusion buffer (mM): 96 NaCl, 2 KCl, 1.8 BaCl2, 5 
HEPES, 0.5% DMSO, pH 7.5. NMDA was applied in combination with a saturating 
concentration of glycine (50 µM). Oocytes were preincubated with externally applied 
inhibitors in Barth’s solution followed by inclusion of inhibitor in the recording solution. 
PregS was applied as 100 µM, except where indicated, and all concentrations of PregS 
appeared soluble in 0.5% DMSO. 
Data analysis. To pool results from multiple oocytes, baseline responses to NMDA were 
established and peak NMDA responses in the presence of PregS were expressed to reveal 
response augmentation. Rapid enhancement of the NMDA response by PregS was 
defined as %P(rapid) = (INMDA+PregS(simultaneous)/INMDA– 1) & 100, the % increase in peak 
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current (%P) induced by NMDA + PregS, as compared to the peak current induced by 
application of NMDA in the absence of PregS. For purpose of analysis, delayed 
enhancement of the NMDA response is defined as %P(delayed) = (INMDA+PregS(10 
min)/INMDA+PregS(simultaneous) – 1) & 100, the percentage increase in the response to NMDA + 
PregS when applied after a 10 min preincubation with PregS, as compared to the 
response elicited when NMDA and PregS are applied simultaneously. For example, if 
rapid potentiation increases the response by 100% and delayed enhancement of the 
NMDA response also increases the response by an additional 100%, then the NMDA 
response after a 10 min exposure to PregS is 400% of the response in the absence of 
PregS. Significance testing was by 2-tailed t-test. EC50s were estimated by nonlinear 
regression using the logistic equation. 
Cell Culture. Primary rat neocortical cultures were prepared from E18 embryos 
maintained 7 days in vitro as described previously  (McLean et al., 2000).  
Confocal Ca2+ imaging of Xenopus oocytes and neocortical cells in culture. Oocytes 
were injected with 50 nl 1 mM fluo-3 (penta ammonium salt, F1240; Molecular Probes, 
OR)  (Jaconi et al., 1997).  Confocal images were acquired in real time using a Zeiss 
Axiovert 150M laser scanning confocal microscope with a Plan-neofluor 10x/0.3 
objective lens at 8 sec per frame.  Oocytes were positioned in a 14 mm glass microwell 
containing 2 ml Ca2+-free Ba-Ringer and the focus was adjusted to image the cross-
section of greatest diameter, approximately through the center of the oocyte.  Oocytes 
exhibited a low level of fluorescence in the absence of fluo-3 injection. Gain was 
adjusted such that fluo-3 injected oocytes exhibited minimal visible fluorescence, and this 
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gain setting was used for all imaging.  The oocyte was initially imaged in saline to 
establish a stable baseline and then 2 ml of PregS in Ba-Ringer was superfused to yield a 
final concentration of 100 µM PregS.  Fluorescence was measured with an argon laser 
(488 nm wavelength) and an emission filter (band path 505 – 530 nm).  The fluorescence 
signal intensity for each oocyte was calculated using the measurement histogram function 
of the Carl Zeiss LSM Image Examiner software.  Values for each oocyte were divided 
by the first value from the imaging of that oocyte to give a change in fluorescence from 
the base line.  
Neocortical cells were plated on polylysine treated glass bottom dishes and maintained in 
vitro for 7 days prior to imaging.  The cells were incubated for 20 min with Fluo-4 
acetoxymethyl ester (AM), the cell permeable ester of the fluorescent calcium indicator 
(F-14201, Molecular Probes, OR).  The confocal images were acquired in real time using 
a Zeiss Axiovert 150M laser scanning confocal microscope with a C-Apochromat 40x/1.2 
40x water immersion objective at 1frame/s.  Culture dishes initially contained 2 ml of 
Ca2+-free HEPES buffered saline. The gain was kept constant. After baseline imaging, 2 
ml of PregS was perfused into the culture dish to yield a final concentration 50 µM.  
Fluo-4 fluorescence was measured with an argon laser and an emission filter and changes 
in Ca2+ levels were determined as described above.  
Labeling and purification of surface proteins. Primary rat neocortical cells were treated 
for 10 min at room temperature with 100 mM PregS or vehicle (0.1% DMSO) in Ca+2-
free HEPES-buffered saline. Cell-surface proteins were biotinylated with membrane-
impermeant biotinamidocaproate N-hydroxysuccinamide ester and extracts prepared as 
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described previously  (Martin et al., 1999) with the following modifications: cortical 
cultures were biotinylated for 10 min at 25˚C. Protein extracts were prepared in ice-cold 
1% (v/v) Nonidet P-40, 0.1% (w/v) SDS, 10% (v/v) glycerol, 50 mM Tris–HCl, 150 mM 
sodium chloride with protease inhibitors (Roche).  Extract protein concentration was 
determined and equal amounts of protein from vehicle and PregS-treated cells were 
retained (Total) for western blotting. Equal amounts of protein from the remaining lysate 
of each treatment group were affinity-purified with NeutrAvidin Agarose Resin (Thermo 
Fisher Scientific) at 4˚C overnight, then pelleted and resuspended in extraction buffer 
three times to remove unbound protein. The final pellet was heated at 80˚C in 1:20 (v/v) 
"-mercaptoethanol-supplemented Tris-Glycine SDS Sample buffer (Invitrogen) to 
dissociate the neutravidin-biotin conjugate, and equal volumes of the resulting samples 
(Biotinylated) were used in western blots.   
Antibodies. The following antibodies were used: mouse anti-glutamate receptor NR1 
(1:1000 [clone 54.1] BD Pharmingen), mouse anti-sodium potassium ATPase (1:1000 
[clone 464.6] Abcam), mouse anti-valosin containing peptide (1:5000 [clone 5] Abcam). 
Antibodies were detected with the appropriate HRP-conjugated secondary antibody, 
Protein A-HRP (1: 4000, Zymed) or goat anti mouse IgG F(ab)2 fragment-HRP (1:4000, 
Abcam). 
Western blots. Protein extracts were separated by SDS polyacrylamide gel 
electrophoresis on 6% tris-glycine gels, transferred to nitrocellulose membranes 
(Invitrogen) and polypeptides were detected by immunoblotting followed by enhanced 
chemiluminescence (GE Healthcare) according to standard methods  (Martin et al., 
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1999). X-ray film (CL-Xposure, Fisher Scientific) was scanned using a Molecular 
Dynamics Personal Densitometer SI Model 375 and quantified using Image Quant TL 
software (Amersham Biosciences). Increasing amounts of total protein were run on each 
gel, probed with anti-NR1 antibody, and quantified to verify that densitometric analysis 
was performed within the linear range of the detection system. Surface NR1 band 
intensity was quantified only if band intensity was within the linear range of total NR1 
band intensity. Surface protein is defined as the ratio of biotinylated to total protein band 
intensity, and surface and total protein is expressed as % vehicle-treated control.  
Electrophysiological recordings of primary neurons. Dissociated 7-day chick embryo 
spinal cord neurons (2-4 weeks in culture) were prepared as described  (Farb et al., 1979). 
Whole-cell currents were recorded by as described  (Park-Chung et al., 1997). Patch 
electrodes (5-10 M') filled with intracellular solution containing (in mM) 153 CsCl, 10 
EGTA, and 10 HEPES (pH to 7.2 with CsOH). Bath solution (in mM): 150 NaCl, 4 KCl, 
1 CaCl2, and 10 HEPES (pH to 7.2 with NaOH).  For some experiments, a Ca2+-free 
solution was used in which 1 mM BaCl2 was substituted for CaCl2 (Ba-buffer). Drug 
solutions were applied to single neurons (23 - 25°C; holding potential -70 mV) by 
pressure ejection (15 psi) from seven-barrel borosilicate glass pipettes positioned 
approximately 50 µm from the neuronal soma.  
 
Results 
Enhancement of the NMDA induced current by PregS exhibits rapid and delayed phases  
As previously reported  (Wu 1991), simultaneous application of NMDA and PregS 
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results in rapid potentiation of the NMDA response of chick spinal cord neurons in 
culture, reflecting allosteric modulation of NMDAR activation. The peak current 
response to a 10 s application of 30 µM NMDA + 100 µM PS was increased by 167 ± 
29% (n=3) over the response to 30 µM NMDA alone. However, with continued exposure 
to PregS, a further, delayed phase of potentiation became apparent (Fig. 1A), with the 
NMDA response after 180 s increased by 359 ± 58% over the initial response to NMDA 
alone (i.e., 4.6 times the initial NMDA response). Both rapid and delayed enhancement of 
the NMDA response by PregS are reversible, with the NMDA-induced current returning 
to control 4.5 min after washout of PregS. Replacement of Ca2+ with Ba2+ in the 
extracellular solution had no significant effect (p > 0.05, unpaired t-test) on the delayed 
potentiation the NMDA response by PregS; the response to a 10 s application of NMDA 
+ PregS was increased by 87 ± 36% compared to NMDA alone, which increased to 261 ± 
51% potentiation (n = 4) after 180 s of exposure to PregS  (Fig. 1B).    
 To determine whether the delay in enhancement is imposed by the time required 
for PregS to reach an intracellular target, 100 µM PregS was added to the intracellular 
buffer in the whole-cell recording electrode to saturate intracellular sites for at least 60 
sec after obtaining the whole-cell configuration and before extracellular application of the 
same concentration of PregS. The time course of PregS potentiation was, however, 
unaltered (p > 0.05, unpaired t-test) by the inclusion of PregS in the intracellular solution 
(Fig. 1C).  Potentiation by PregS was 128 ± 40% after 10 s and 481 ± 140% (n = 4) after 
180 s, arguing that delayed potentiation, like rapid potentiation, is mediated by a site 
associated with the extracellular membrane surface.  
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The NR2 subunit controls the delayed phase of potentiation  
NMDARs comprised of various subunit combinations were expressed in oocytes to ask 
whether the NR2 subunit might affect delayed potentiation. Similar to observations in 
neurons, both rapid and delayed phases of potentiation are observed. PregS rapidly and 
reversibly potentiates the peak current elicited by NMDA on cells expressing NR1/2A 
receptors. However, the NMDA response continues to increase with a time constant of ~3 
min, resulting in a total potentiation of 200 - 370% (Fig. 2A, B). The delayed onset 
NMDA response returns to control 2 - 3 min after removal of PregS, showing that 
delayed potentiation is reversible (Fig. 2B). Whereas the response to application of 
NMDA alone typically exhibited a rapid rise and a “flat-topped” response profile that 
was stable over a 10 s application interval, responses in the presence of PregS typically 
exhibited a profile with a slight upward slope, likely reflecting the progress of delayed 
potentiation (Fig. 2A). Repetitive application of NMDA as shown in Figs. 1 and 2 was 
not necessary as application of PregS for 10 min prior to NMDA + PregS was sufficient 
to elicit delayed potentiation. For subsequent experiments, the magnitudes of rapid and 
delayed potentiation were assessed by comparing the response to NMDA alone, the 
response to NMDA + PregS, and the response to NMDA + PregS applied after 10 min of 
exposure to PregS. Delayed potentiation of the NMDA response by PregS is observed in  
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Fig. 1. PregS induces delayed onset potentiation of the NMDA response in neurons. 
PregS (100 !M) and NMDA are applied by pressure ejection to primary embryonic 
spinal cord neurons in culture while recording by whole-cell voltage clamp. (A) 
Potentiation of the NMDA response by PregS increases upon continued exposure to 
PregS and typically levels off after about 85 s. Typical results are shown. Two minutes 
elapsed between the initial control application of NMDA and the beginning of PregS 
application; 4.5 min elapsed between the termination of PregS application and the final 
control NMDA response. (B) Delayed enhancement of the NMDA induced current by 
PregS persists when Ba2+ is substituted for Ca2+in the perfusion buffer. (C) Delayed 
increase in the NMDA induced current by PregS persists when PregS is included in the 
intracellular electrode buffer. A minimum of 1 min was allowed after establishment of 
the high resistance seal on the chick spinal cord neurons to permit equilibration of PregS.  
Work completed by K. Richards 
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Fig. 2. Delayed onset potentiation by PregS is recapitulated by recombinant 
NMDARs expressed in oocytes. PregS and NMDA are applied by bath perfusion to 
oocytes expressing NR1/2A subunits while recording in the two-electrode whole-cell 
voltage clamp mode. (A) Potentiation of the NMDA response by PregS increases upon 
continued exposure to PregS and typically levels off after 7 – 10 min. Black bars indicate 
successive applications of NMDA (300 !M). Breaks between traces are 1.3 - 1.8 min (see 
panel B for times). PregS (100 !M) was added to the perfusion buffer at t = 0 and 
included for 7 min (overlying black bar).  (B) Peak NMDA induced currents determined 
as in (A) are normalized to the average response before application of PregS beginning at 
t = 0. Smooth curve reflects an exponential fit (t = 184 sec). Error bars indicate S.E.M. (n 
= 3). Arrows indicate rapid and delayed components of potentiation. Unless otherwise 
indicated, NMDA (300 !M) and PregS (100 !M) in 0.5% DMSO were used with 
Xenopus oocytes as the standard test concentrations below. Oocytes were perfused with 
Ba-Ringer and voltage-clamped at –70 mV. Work completed by E. Kostakis 
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oocytes expressing NR1/2A or NR1/2B receptors but not in oocytes expressing NR1/2C 
or NR1/2D receptors (Fig 3A).  This is in contrast to rapid modulation, wherein PregS 
initiates rapid positive modulation of NR1/2A and NR1/2B receptors but negative 
modulation of NR1/2C and NR1/2D receptors  (Malayev 2002). In the case of NR1/2A 
receptors, the concentration-response curve for delayed potentiation by PregS exhibits a 
25-fold greater potency (EC50 850 nM) than for rapid potentiation (EC50 21 µM) (Fig. 
3B). Thus, PregS exhibits substantial potentiation and selectivity at a much lower 
concentration: at100 nM PregS (Fig. 3B) there is substantial delayed potentiation yet 
little or no rapid potentiation. By contrast, in the case of NR1/2B receptors, 100 nM 
PregS exhibits no detectable delayed or rapid potentiation (Fig. 3C).   
 
Delayed potentiation is independent of rapid potentiation  
The observation that the PregS EC50 for delayed potentiation of NR1/2A receptors is 25-
fold lower than for rapid potentiation suggests that rapid and delayed potentiation are 
independent processes. As shown in Figure 4, PregS at a concentration of 100 nM 
produces no rapid potentiation of the 10 µM NMDA response of NR1/2A receptors, yet 
nevertheless induces 45 ± 3% delayed potentiation.  
 As previously reported, rapid PregS potentiation is eliminated in NR1-1a/c4 
receptors, where c4 is a chimeric NR2 subunit in which steroid modulatory domain 1 
(SMD1) encompassing the J-K helices and the M4 domain (S759–I836) of NR2B is 
replaced with the equivalent region of NR2D  (Jang 2004). As shown in figure 3A, 
delayed potentiation by PregS persists with this construct, arguing that delayed 
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potentiation is not contingent on rapid positive allosteric modulation and acts via a novel 
NMDAR site that is independent of SMD1. 
 
GABAA receptors do not exhibit delayed potentiation 
To determine whether delayed potentiation is limited to NMDARs, !1"2#2s GABAA 
receptors and NR1/2A receptors were co-expressed in oocytes. Whereas the response to 
300 µM NMDA was enhanced when NMDA was applied in combination with 100 µM 
PregS, the response to GABA was substantially inhibited but still readily measurable. 
Moreover, whereas a 10 min pre-exposure of oocytes to PregS produced further 
enhancement of the NMDA response, the amplitude of the GABA response was similar  
to that observed when GABA and PregS were applied simultaneously, indicating the 
absence of a delayed effect of PregS on GABAA receptors (Supplemental Figure 1).  
G-protein activation is involved in delayed potentiation  
The extended time scale of delayed potentiation suggests the involvement of intracellular 
signal transduction pathways. To test for GPCR involvement, potentiation by PregS was 
examined ~4 h after injection of oocytes with 500 pg of pertussis toxin (PTx). Delayed 
potentiation was significantly diminished in PTx-injected oocytes. To test for the 
involvement of PLC, we examined the effects of U-73122, an inhibitor of G protein-
mediated PLC activation  (Smith 1990; Thompson 1991; Smallridge 1992). Oocytes 
treated with U-73122 (20 µM, 1 h) exhibit reduced responses to NMDA (~10% of 
control, data not shown), and delayed potentiation is absent. Oocytes treated  
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Fig. 3. Delayed potentiation by PregS is independent of fast potentiation and 
selective for NR1/2A (and NR1/2B). (A) Delayed potentiation is observed with 
NR1/(2A or 2B) but not NR1/(2C or 2D) or the NR1/NR2D-B chimera (c4) that is 
inactive with respect to fast potentiation. NR1 cRNA was co-expressed in oocytes with 
cRNA for the NR2A, NR2B, NR2C, NR2D or c4 subunit. Peak currents elicited by 
application of NMDA + PregS, either simultaneously or after 10 min perfusion with 
PregS, are expressed relative to the NMDA-induced current in the absence of PregS. * 
Indicates a significant (p < 0.001, paired 2-tail t-test) increase over simultaneous addition 
of PregS and NMDA. Error bars indicate S.E.M. (n = 7 - 12). (B) Concentration-effect 
curves for rapid (EC50 21 µM) and delayed (EC50 850 nM) increase in NR1/2A receptors. 
To measure rapid potentiation, oocytes were exposed simultaneously to 300 µM NMDA 
plus the indicated concentration of PregS. To measure delayed potentiation, oocytes were 
perfused for 10 min with the indicated concentration of PregS, then exposed to NMDA + 
PregS. Delayed potentiation is defined as the additional percentage potentiation of the 
peak NMDA response after 10 min relative to the response when PregS and NMDA are 
applied simultaneously. Arrows indicate EC50. Error bars indicate S.E.M. (n = 5 - 7) (C) 
Concentration-effect curves for rapid (EC50 19 µM) and delayed (EC50 33 µM) 
potentiation with NR1/2B receptors indicate lower potency but higher efficacy for 
delayed potentiation by PregS. Arrows indicate EC50. Error bars indicate S.E.M. (n = 5 – 
7 oocytes). Work completed by E. Kostakis, M.-K. Jang 
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Fig. 4. Delayed potentiation but not rapid potentiation is induced by 100 nM PregS 
in oocytes expressing NR1/2A receptors. Using a reduced concentration of 100 nM 
PregS, substantial delayed potentiation is observed without detectable rapid potentiation. 
(A) Typical responses of oocytes expressing NR1/2A receptors to 10 µM NMDA alone, 
10 µM NMDA + 100 nM PregS (applied simultaneously), and 10 µM NMDA + 100 nM 
PregS after 10 min preincubation with 100 nM PregS. (B) Averaged values of normalized 
peak current responses for rapid and delayed increase in NR1/2A receptors (n = 8 - 10). 
When added simultaneously with NMDA, PregS produced negligible potentiation of the 
NMDA response (1 ± 2%), whereas after 10 min preincubation with 100 nM PregS the 
response to NMDA was enhanced by 45 ± 3% Error bars represent S.E.M (n = 8 - 10). * 
Indicates a significant difference between rapid and delayed potentiation, p<0.0005. 
Work completed by E. Kostakis 
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with the inactive analog U-73343 are unaffected (Table 2). Notably, none of the 
pharmacological treatments affected rapid potentiation by PregS (Table 2). 
PKC mediates delayed but not rapid potentiation 
To investigate the role of protein kinases in delayed potentiation by PregS, we examined 
the effect of PregS in oocytes treated with protein kinase inhibitors and activators. 
Pretreatment of cells expressing NR1/2A receptors with the PKC activator phorbol 12-
myristate 13-acetate (PMA) substantially increases the NMDA response in the absence of 
PregS (404 ± 19%, n = 8), but does not significantly affect rapid potentiation by PregS, 
whereas delayed potentiation by PregS is abolished (Table 3). Because PMA itself 
enhances the NMDA response (Supplemental Figure 2), this likely reflects saturation of 
the PKC-dependent pathway by PMA.  Pretreatment of cells with staurosporine, a broad-
spectrum inhibitor of serine/threonine protein kinases, does not affect the magnitude of 
the control NMDA response, but significantly reduces delayed potentiation (Table 3). 
Similar results are observed with the PKC inhibitor bisindolylmaleimide I. In contrast, 
the nonreceptor protein kinase inhibitor genistein, the protein kinase inhibitor CK2  
(Litchfield 2003), the casein kinase II inhibitor 5,6-dichloro-1-b-d-
ribofuranosylbenzimidazole (DRB), and the MEK inhibitor U0126 are without effect on 
delayed potentiation. Delayed potentiation by PregS is unaffected by treatment with the 
insulin receptor tyrosine kinase inhibitor tyrphostin A47 (10 min, 100 µM), which blocks 
insulin-induced potentiation of the NMDA response  (Skeberdis 2001b) (Table 3). None 
of the inhibitors tested altered rapid potentiation, demonstrating that distinct mechanisms 
mediate rapid and delayed potentiation. 
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Table 2. Second messenger pathways 
Treatment Target Total 
Potentiation 
Rapid 
Potentiation  
Delayed 
Potentiation  
Vehicle  203 ± 15%  68 ±  4%  76 ±  7% (15) 
PTx Gi/Go 140 ± 13%  72 ±  4%  40 ±  6% (13) † 
U-73343 inactive 
control 
182 ± 17%  62 ±  6%  75 ±  7% (6) 
U-73122 PLC  83 ± 6%  60 ±  5%  14 ±  5% (8)  ** 
Table 2. Cells were treated with the indicated inhibitor prior to measuring the increase in 
peak response to NMDA (300 !M) produced by PregS (100 !M). Treatment conditions 
were: U-73122/U-73343, 1 h, 20!M in Barth’s solution plus 0.4% DMSO; PTx, 50 nl 
injection of 500 pg PTx in 5 mM Tris, 0.05 mM EDTA, 0.015% CHAPS, pH 8. 
Statistically significant vs. vehicle (2-tailed t-test): ** p < 0.005; † p < 0.001. 
Work completed by E. Kostakis 
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Table 3. Intracellular signal transduction pathways 
 
Treatment 
 
Target 
Total 
Potentiation 
Rapid 
Potentiation  
Delayed 
Potentiation  
Vehicle  189 ± 8% 65 ± 3%  75 ±  2% (7) 
PMA  PKC  76 ± 5% 65 ± 3%    6 ± 1% (8)  *  
Staurosporine protein 
kinase 
111 ± 7%  67 ± 2%  25 ± 3% (8) 
DRB casein kinase 173 ± 3% 60 ± 5%  71 ± 6% (4) 
Genistein nonreceptor 
protein 
kinase 
184 ± 6% 64 ± 4%  73 ± 3% (5) 
Vehicle  199 ± 8% 66 ±  5%  81 ±   5% (8) 
Bisindolyl-
maleimide I 
PKC 118 ± 12% 65 ±  3%  31 ±  7% (8)  ** 
H89 PKA 204 ± 9% 63 ±  3%  87 ±  4% (6) 
Vehicle  226 ± 18% 70 ±  4%  91 ±  6% (8) 
U-0126 MEK 232 ± 22% 77 ±  8%  91 ±  6% (6)  
Vehicle  194 ± 19% 64 ±  8%  79 ±  8% (6) 
Tyrphostin 
A47 
insulin 
receptor tyr 
kinase 
210 ± 24% 72 ±  8%  80 ±  9% (6) 
Table 3. Cells were treated with the indicated pharmacological inhibitor prior to 
measuring the rapid and delayed (10 min) increase in peak response to NMDA (300 !M) 
produced by PregS (100 !M). Treatment conditions were: PMA, 10 min, 2 !M in Barth’s 
solution plus 0.5% DMSO; Bisindolylmaleimide I, 2-3 h, 2 !M in Barth’s solution plus 
0.5% DMSO; H-89, 1-2 h, 4 !M in Barth’s solution plus 0.5% DMSO; Staurosporine, 
2h, 2 !M in Barth’s solution plus 0.5% DMSO; DRB, 2h, 60 !M in Barth’s solution plus 
0.5% DMSO; genistein, 2h, 50 !M in Barth’s solution plus 0.5% DMSO; U-0126, 1 h, 20 
!M in Barth’s solution plus 1% DMSO; Tyrphostin A47, 20 min, 100 !M in Barth’s 
solution plus 0.5% DMSO. Statistically significant vs. vehicle (2-tailed t-test): * p < 0.01; 
** p < 0.005. Work completed by E. Kostakis 
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! receptors do not mediate delayed potentiation 
To test for involvement of $1 receptors, oocytes were pretreated with the $ receptor 
ligands BD 1063 (30 µM) or haloperidol (10 µM). Delayed potentiation was unaffected 
(control: 80 ± 6%, BD-1063, 74 ± 9%, haloperidol: 72 ± 5%; n =6-13), indicating that $1 
receptors do not play a role in potentiation of the NMDA response by PregS. 
Delayed potentiation by PregS requires Ca2+ release from intracellular stores. 
Pharmacological evidence for the involvement of PLC and PKC in delayed potentiation 
suggests a Ca2+ mediated pathway. To evaluate the role of Ca2+, oocytes were injected 
with EGTA 30 min prior to recording.  As shown in Table 4, delayed potentiation is 
significantly reduced by intracellular chelation of Ca2+. Because recordings were 
routinely carried out in Ca2+-free Ba-Ringer, the most likely source of Ca2+ is release from 
intracellular stores. We therefore examined the effect of the endoplasmic reticulum Ca2+-
ATPase inhibitor thapsigargin, which depletes Ca2+ stores and elevates [Ca2+]i. After 
incubation with thapsigargin (1 mM for 1 hr), oocytes exhibit ~700% increase in the 
NMDA current compared to untreated oocytes (data not shown), in agreement with 
previous reports  (Nishizaki 1999; Skeberdis 2001a). Rapid potentiation is unaltered after 
thapsigargin treatment, but delayed potentiation is eliminated. Delayed potentiation is 
abolished in oocytes injected with 50 nl of 1mM heparin (Table 4), an inhibitor of the 
oocyte IP3 receptor, but persists in control oocytes injected with the inactive analog de-N-
sulfated heparin  (Noh 1998).  
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Table 4. Calcium signaling 
 
Treatment 
 
Target 
Total 
Potentiation 
Rapid 
Potentiation  
Delayed 
Potentiation  
de-N-sulfated 
heparin 
inactive 
control 
227 ± 26%  77 ±  7%  91 ±  9% (8) 
Heparin IP3 receptor 110 ± 8%  86 ±  7%  12 ±  5% (9) ** 
Vehicle  208 ± 19%  61 ±  7%  91 ±  7% (10) 
EGTA [Ca2+]i 111 ± 9%  69 ±  5%  25 ±  5% (11) ** 
Vehicle  197 ± 15%  72 ±  5%  74 ±  6% (7) 
Thapsigargin SERCA 101 ± 6%  73 ±  5%  16 ±  4% (8) † 
Table 4. Cells were treated with the indicated inhibitor prior to measuring the rapid and 
delayed (10 min) increase in peak response to NMDA (300 µM) produced by PregS (100 
µM). Treatment conditions were: EGTA, 50 nl injection of 5 mM EGTA in water; 
heparin/de-N-sulfated heparin, 1 mM, 50 nl injection; thapsigargin, 1 h, 1 mM in Barth’s 
solution plus 0.1% DMSO. Statistically significant vs. vehicle (2-tailed t-test): ** p < 
0.005; † p < 0.001.Work completed by E. Kostakis 
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To test the hypothesis that PregS stimulates release of Ca2+ from intracellular stores, 
[Ca2+]i was visualized in oocytes by confocal microscopy using fluo-3 (Fig. 5). Oocytes 
expressing NR1/2A receptors exhibit a transient increase in Ca2+ fluorescence beginning 
within seconds of PregS, but not vehicle, addition, peaking after about 50 sec and 
subsiding to baseline after 3 - 4 min. PregS had no effect on Ca2+ fluorescence in oocytes 
that were uninjected or injected with vehicle, demonstrating that NMDA receptors are 
essential for PregS-induced Ca2+ release. Oocytes expressing NR1/2D receptors failed to 
exhibit an increase in Ca2+ fluorescence, demonstrating subunit specificity.  
The increase in Ca2+ fluorescence is primarily localized close to the membrane, consistent 
with the location of IP3-releasable Ca2+ stores in oocytes  (Yao et al., 1995). The PregS-
induced increase in Ca2+ fluorescence was observed in Ca2+-free Ba-Ringer, indicating 
that the increase in [Ca2+]i fluorescence is due to Ca2+ release from intracellular stores, 
and not entry of Ca2+ via NMDAR channels. A control experiment in which an oocyte 
expressing NR1/2A receptors was exposed to PregS in Ca2+-free/Ba2+-free Ringer 
containing 1 mM EGTA yielded a similar increase in fluorescence.  
To determine whether PregS is similarly capable of increasing intracellular Ca2+ in 
neurons, primary rat neocortical neurons in culture were incubated with the membrane-
permeant Ca2+ indicator fluo-4 AM and exposed to various concentration of PregS. As 
shown in Fig. 6, PregS elicits a large initial increase in neuronal Ca2+ fluorescence that 
diminishes with time but persists over baseline for at least three minutes.  
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Fig. 5. PregS induces intracellular Ca2+ increases in oocytes expressing NR1/2A but 
not NR1/2D receptors.  Cells were injected with 50 nl 1 mM fluo-3 Ca2+ indicator and 
changes in fluorescence during an exposure to PregS were monitored by confocal 
microscopy.  Cells expressing NR1/2A (A - D) exhibit a visible increase in fluorescence 
near the membrane after PregS application.  However, oocytes expressing NR1/2D (E - 
H) and control oocytes (injected with water vehicle without cRNA) (I - L) do not respond 
to PregS.  Images of NR1/2A (A-C), NR1/2D (E - G) and control oocytes (I - K) before 
PregS (A, E, I) and after PregS application (B, C, F, G, J and K). The average response to 
PregS for NR1/2A (D), NR1/2D (H) and control oocytes (L) is represented to the right of 
the Xenopus oocytes images (n = 8). Work completed by S. Martin and E. Kostakis 
 
 
 
 
 
  
 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. PregS induces Ca2+ release in neocortical neurons. Neocortical cells isolated 
from E18 rat maintained in vitro for one week were incubated with fluo-4 Ca2+ indicator.  
Change in fluorescence ($F, arbitrary units) during an exposure to PregS (50 µM in 
0.05% DMSO) was monitored by confocal microscopy.  Images of neocortical cells in 
phase (A), phase with Fluo-4 (B) and with Fluo-4 (C). Neocortical Cells exhibit a visible 
increase in fluorescence in the cell body and processes after PregS treatment (D, E, H and 
I).  Cells exhibit no significant change in fluorescence after vehicle treatment (K and L).  
Images of cells before (D and H) and after (E and I) PregS treatment, and before (K) and 
after (L) vehicle treatment are shown. The time course of the responses to PregS of 
selected cell bodies, designated by arrows in panel D, and of the entire field are shown in 
panels F and G, respectively. The time course of the response to PregS of a neocortical 
cell process, designated by the arrowhead in panel H, is shown in panel J. The time 
course of the response to vehicle application of selected cell bodies (designated by arrows 
in panel K) and of the entire field are shown in panels M and N. Scale bar, 10 µm. Work 
completed by C. Smith and S. Martin  
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Exocytosis is required for delayed potentiation 
Delayed potentiation by PregS was blocked by injection of oocytes with botulinum toxin 
type A (BoNT A), a zinc endoprotease produced by bacteria of the genus Clostridium 
that cleaves SNAP-25 and prevents SNARE regulated exocytosis  (Pellizzari et al., 1999; 
Lan et al., 2001a). Rapid potentiation was insensitive to BoNT A (Fig. 7), indicating that 
delayed, but not rapid, potentiation requires exocytosis. Treatment with BoNT A alone 
did not reduce the amplitude of the NMDA response, arguing that most NMDARs do not 
exhibit rapid recycling in the absence of PregS. Similarly, delayed potentiation was 
significantly inhibited by Brefeldin A (BFA) (control: 70 ± 3%, BFA: 42 ± 5%, p < 0.01, 
n = 13), which disassembles the Golgi complex and inhibits vesicular transport  (Oda 
1987; Misumi 1986; Klausner 1992).  
 
PregS increases the functional cellular response to NMDA via increasing surface 
receptors. 
To determine whether delayed potentiation is due to an increase in the number of 
functional NMDARs on the cell membrane, we examined tail currents elicited by a 
depolarizing voltage jump following complete NMDAR blockade by the open-channel 
blocker 9-aminoacridine. Block by 9-aminoacridine (9-AA) traps activated NMDARs in 
a nonconducting state from which the co-agonists NMDA and glycine are unable to 
dissociate, synchronizing all functional NMDAR channels in a blocked open 
conformation (Fig. 8A)  (Benveniste and Mayer, 1995). Block by 9-AA is voltage 
dependent, such that a depolarizing voltage step to +70 mV induces rapid (< 3 ms)  
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Fig. 7. Delayed potentiation of the NMDA response by PregS requires exocytosis of 
NMDARs. (A) Prior exposure to PregS for 10 min enhances whole-cell currents elicited 
by co-application of NMDA and PregS to oocytes expressing NR1/2A receptors. Vh = -
70 mV. (B) Microinjection of BoNT A (50 ng, 5 h before recording) reduces PregS 
induced delayed potentiation without affecting rapid potentiation. BoNT A was reduced 
with 20 mM DTT at room temperature 1 h before use. Controls were injected with 10 
mM DTT in 1 mg/ml BSA (n = 10). (C) BoNT A reduces delayed potentiation (p < 
0.00001, n = 9) with no effect on rapid potentiation. Error bars represent s.e.m based 
upon the number of oocytes tested. Work comleted by E. Kostakis 
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Fig. 8. PregS increases the number of functional surface NMDARs in oocytes 
expressing NR1/2A receptors. (A) NMDA (300 µM) and 9-AA (100 µM) co-applied to 
oocytes expressing NR1/2A receptors result in a transient inward current as NMDA 
activated channels are blocked by 9-AA (a voltage dependent open channel blocker). As 
the holding potential is switched from –70 to +70 mV, an outward tail current reflecting 
9-AA unblock of NMDAR channels ensues (black traces). Cells were then exposed to (B) 
vehicle (Ba-Ringer) or (C) PregS for 10 min and the 9-AA block and unblock sequences 
repeated (blue traces). Peak tail currents after baseline subtraction are expressed relative 
to the control current (black trace) from the same cell (p2/p1). (D) The peak current ratio 
p2/p1 for PregS treated oocytes (blue bar, n = 8) is significantly higher than for vehicle 
treated oocytes (white bar, n = 6). * Relative current p < 0.00001, unpaired 2-tail t-test. 
Work completed by E. Kostakis 
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dissociation of 9-AA, such that all of the NMDAR channels that have accumulated in the 
blocked state reopen nearly simultaneously after depolarization  (Benveniste and Mayer, 
1995; Chen et al., 1999). The resulting tail current is independent of the efficacy of 
NMDA and proportional to the number of activatable receptors  (Horak et al., 2006). The 
amplitude of the tail current after a voltage jump from -70 to +70 mV is more than 
doubled following 10 min exposure to PregS (Fig. 8B), indicating that the number of 
functional surface NMDARs is increased. This is similar to the magnitude of delayed 
potentiation, arguing that delayed potentiation is due to an increase in the number of 
functional surface receptors.  
PregS increases surface NMDARs in neurons. 
To determine whether the PregS increases surface NMDARs in neurons, rat neocortical 
neurons were exposed to PregS for 10 min and surface proteins labeled with biotin. 
Following affinity purification on an avidin column, levels of total and biotinylated 
surface NR1 were assessed by Western blot. As quantified in Fig. 9, PregS increases 
surface NR1 by 62 ± 25% (p=0.033, students t-test, n=6). Levels of total NR1 were not 
increased with PregS treatment (total NR1 for PregS-treated as a percent of control: 89 ± 
10%, p=0.291, students t-test, n=6). Na/K ATPase  (Kaplan 2002; Zhang 2009) and 
valosin containing protein (VCP)  (Zhang 1994; Kobayashi et al., 2002) were used as 
surface and intracellular markers, respectively. Biotinylated Na/K ATPase was observed 
in all experiments (n = 6), while biotinylated VCP was below the limit of detection.   
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Fig. 9. PregS increases surface NR1 subunits on neocortical neurons. (A) 
Representative immunoblot of surface NR1 levels in neocortical neurons exposed to 
PregS for 10 min as compared with vehicle. Surface biotinylated proteins were affinity-
purified and analyzed with a fraction of total cellular proteins by immunoblotting with 
antisera to NR1, surface Na+/K+ ATPase (positive control), or cytoplasmic VCP (negative 
control). (B) Quantitation of the effect of PregS (50 µM, 0.1% DMSO, 10 min) on total 
and surface-biotinylated NR1. (Left panel) Immunoreactivity in biotinylated aliquots as a 
fraction of total NR1 expressed as percent of vehicle. PregS induced a 62 ± 25% increase 
(p = 0.033, n = 6 experiments, students t-test) in the biotinylated fraction of NR1. (Right 
panel)  There was no change in total NR1 levels with PregS treatment (p = 0.291, n = 6 
experiments, students t-test). Work completed by C. Smith and S. Martin 
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Discussion 
 The ability of nerve cells to regulate receptor number, composition, and 
distribution is central to nervous system function.  Neuronal activity regulates NMDA 
receptor trafficking via both phosphorylation-dependent and phosphorylation-
independent pathways  (Chen and Roche, 2007; Lau 2009), and insulin potentiates the 
NMDA response via the insulin receptor-activated tyrosine kinase  (Skeberdis 2001b). 
 The hypothesis of a linkage between ionotropic glutamate receptors and 
metabotropic Gi-protein coupled pathways via a “noncanonical” signal transduction 
mechanism that is not triggered by ion current suggests a pathway for crosstalk between 
the large classes of ionotropic and metabotropic systems. Results consistent with this can 
be found in several reports  (Rodríguez-Moreno and Sihra, 2007). For example, the 
treatment of rat cortical neurons in culture with AMPA in the absence of extracellular 
permeant cations decreases PTx-mediated ADP glycosylation of Gai1 and induces rapid 
association of Gai1 with GluR1 AMPA receptors  (Wang 1997). Similarly, exposure of 
mouse dorsal root ganglion neurons to kainate elevates [Ca2+]i via a PTx-sensitive, 
phospholipase C-dependent mechanism that is not dependent upon ion permeation, and 
this effect is absent in neurons from GlurR5-deficient mice  (Rozas 2003).  A direct 
interaction with a G-protein seems unlikely as NMDARs do not exhibit homology to 
GPCR G-protein interacting domains and are not known to interact directly with G-
proteins. Direct protein-protein coupling and functional crosstalk between NR1/2A 
NMDARs and D1 dopamine receptors  (Nai 2010; Martina and Bergeron, 2008; Pei  
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2004) is suggestive of a receptor subtype selective mechanism for crosstalk. This raises 
the possibility of cell signaling mediated crosstalk.  
 In this report, the results show that PregS stimulates a sustained increase in the 
NMDA response that develops over several minutes, rather than milliseconds to seconds, 
and results from the incorporation of additional functional receptors into the surface 
membrane. The delayed onset PregS-induced augmentation of the NMDA response is 
subunit-specific and, unlike the rapid phase of potentiation, requires G-protein coupled 
activation of PKC and PLC and increased [Ca2+]i. When combined with the effect of 
rapid positive allosteric modulation total enhancement of the NMDA response averages 
200% but can reach up to 400% in a given neuron.  
 Delayed potentiation of the electrophysiological response is mediated by the 
release of Ca2+ from intracellular stores. EGTA, heparin, and thapsigargin inhibit delayed 
potentiation suggesting a role for Ca2+.  Consistent with the results of inhibitors, Ca2+ 
imaging using fluo-3 shows that PregS releases Ca2+ from intracellular stores in oocytes 
expressing NR1/2A receptors. In contrast to some other agents that release intracellular 
Ca2+, such as acetylcholine  (Dascal 1985) and lysophosphatidic acid  (Jaconi 1997), 
PregS does not elicit detectable activation of Ca2+-sensitive chloride current in oocytes, 
suggesting that PregS induced Ca2+ release is localized or limited in magnitude. Oocytes 
expressing NR1/2D receptors did not exhibit delayed modulation of the NMDA response 
or PregS-induced Ca2+ release, suggesting that the interaction of PregS with NR1/2D 
receptors is unable to activate the signaling pathway that releases intracellular Ca2+ and 
leads to increased NMDAR surface expression. 
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 BoNT A blocks delayed potentiation, arguing that PregS stimulates delivery of 
NMDARs to the cell surface by SNARE mediated exocytosis. The vesicular trafficking 
inhibitor BFA  (Klausner 1992), which inhibits NMDA-induced LTP and rapid 
membrane insertion of AMPA receptor subunits  (Broutman and Baudry, 2001), similarly 
inhibits delayed potentiation, arguing that NMDARs are inserted into the membrane from 
an intracellular pool via a functional secretory pathway. The ability of PregS to increase 
delivery of NMDARs to the cell surface as confirmed by immunoprecipitation of surface-
labeled NMDARs, demonstrates a significant increase in surface NR1 subunits following 
PregS treatment of cortical neurons in culture. 
 Delayed potentiation is reversed ~3 - 5 min after washout of PregS, suggesting 
that the additional surface NMDARs are rapidly re-internalized. The PregS-induced 
increase in surface NMDARs could be due to either stimulation of NMDAR exocytosis 
or to inhibition of NMDAR endocytosis  (Nong 2004). But BoNT A did not reduce the 
NMDA response in the absence of PregS (data not shown), arguing that the latter is not 
the case.  
 Injection of PTx inhibits delayed potentiation, implicating a PTx-sensitive Gi/Go 
protein, and blockade of delayed potentiation by U-73122 implicates G protein mediated 
PLC activation. Although PLC activation is primarily associated with Gq-coupled 
GPCRs, there is evidence that Gi can also participate in PLC-dependent mobilization of 
intracellular Ca2+, likely via the "# subunit  (Mizuta 2011). How PregS activates G-
protein coupled signaling pathways to increase surface NMDARs remains unclear. PregS 
interacts with $1 receptors that couple to Gi in mouse brain membranes  (Ueda 2001), but 
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delayed potentiation is unaffected by the $1 antagonists BD 1063 and haloperidol, 
indicating that delayed potentiation in oocytes is not mediated by $1 receptors. 
 Application of PregS for 10 min in the absence of NMDA or glutamate increases 
the response to a subsequent application of NMDA. As PregS alone does not induce a 
detectable current, activation of the NMDAR channel is not required for delayed 
potentiation. For the same reason, the increase in [Ca2+]i observed when PregS alone is 
applied to oocytes cannot be due to entry of Ca2+ via the NMDAR channel or voltage-
gated Ca2+ channels. Moreover, delayed potentiation by PregS persists when extracellular 
Ca2+ is replaced with Ba2+, which does not stimulate PKC-mediated enhancement of the 
NMDA response  (Zheng et al., 1997). These findings indicate that PregS induces 
increased [Ca2+]i and delayed potentiation of the NMDA response via a pathway that is 
not dependent upon ion permeation through the NMDAR channel.  
Taken together, the results support the model diagrammed in Fig. 10, in which PregS, 
acting through the NMDAR, stimulates Gi/o dependent activation of PLC, resulting in 
production of diacylglycerol (DAG) and IP3, thereby triggering Ca2+ release from 
intracellular stores and stimulating Ca2+ dependent insertion of NMDARs into the surface 
membrane.  
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Fig. 10. Model of signal transduction pathway for delayed onset potentiation of the 
NMDA response by PregS.  Diagram illustrates the proposed intracellular pathways that 
participate in the PregS stimulated trafficking of functional NMDA receptors to the cell 
surface via a non-canonical G-protein, PLC, Ca++ and PKC dependent mechanism. Figure 
by C. Smith 
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 The pathway diagrammed in Fig. 10  is similar to the pathway described for 
potentiation of NMDA responses and NMDAR surface expression by the mGluR agonist 
(1S,3R)-1-amino-cyclopentane-1,3-dicarboxylic acid (ACPD) in oocytes co-expressing 
NR1-4b/NR2A receptors and mGluR1a glutamate receptors  (Skeberdis et al., 2001a), 
which has been reported to mediate postsynaptic long-term potentiation at hippocampal 
mossy fiber synapses  (Kwon and Castillo, 2008).  As with delayed potentiation by 
PregS, enhancement of NMDAR surface expression by ACPD is antagonized by 
staurosporine, BoToxA, U-73122, or intracellular Ca2+ chelation. However, potentiation 
by ACPD requires co-expression of GluR1a  (Lan 2001b; Skeberdis 2001a), whereas 
delayed potentiation and release of intracellular Ca2+ by PregS requires only expression of 
NR1/2A receptors. 
 The location of the recognition site responsible for delayed potentiation by PregS 
remains to be identified. The recognition site for delayed potentiation is likely distinct 
from the site responsible for rapid potentiation, based on (1) substantially higher affinity 
of PregS at inducing delayed than rapid potentiation of NR1/2A receptors, (2) delayed 
potentiation of NR1/2A receptors by 100 nM PregS in the absence of rapid potentiation, 
and (3) delayed potentiation of NR1-1a/c4 receptors without rapid potentiation.  Another 
possibility is that the PregS recognition site that mediates delayed potentiation and [Ca2+]i 
increase is physically located on another protein, with the NMDAR playing a subunit-
specific yet permissive role to enable this interaction. 
 Movement of receptors from the subsynaptic receptor pool to the synaptic 
population and the constitutive trafficking of receptors is essential to the viability and 
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functionality of neurons  (Lau and Zukin, 2007).  Membrane fusion events contribute to 
NMDA receptor-dependent LTP, which in adult rat brain slices is associated with rapid 
Src- and PKC-dependent membrane insertion of NMDARs, pointing to a potential role 
for NMDAR trafficking in synaptic plasticity  (Grosshans 2002).  
 Neuroactive steroids exert modulatory effects on neurotransmission in a variety of 
systems. PregS is endogenously present in human brain, but its concentration in the 
extracellular space is unknown  (Liere 2004; Gibbs 2006). While most neurosteroids are 
neutral hydrophobic molecules, PregS is a negatively charged sulfate ester, potentially 
capable of being stored and selectively released. A PregS-like factor may act as a 
retrograde messenger to mediate long-term enhancement of AMPA receptor function in 
neonatal rat hippocampal slices via presynaptic NMDARs  (Mameli and Valenzuela, 
2006). PregS acts as a cognitive enhancer in vivo  (Gibbs 2006; Schumacher 2008) and 
acts both presynaptically and postsynaptically to enhance synaptic transmission in 
multiple neurotransmitter systems  (Zheng, 2009), but the mechanism of these diverse 
effects is not well understood.   
 Regulation of intracellular Ca2+ release or sequestration is potentially a unifying 
mechanism to account for the diverse effects of this neuroactive steroid on synaptic 
transmission, many of which can be understood in terms of alterations in Ca2+-dependent 
processes, such as the vesicular release of transmitters or delivery of receptors to the cell 
surface. The results suggest that in addition to the well-established ionotropic mechanism 
whereby NMDARs directly transport Ca2+ ions, NMDARs are also capable of regulating 
[Ca2+]i by engaging a noncanonical metabotropic signaling cascade that in turn increases 
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NMDAR surface expression. PregS induced NMDAR upregulation constitutes a novel 
mechanism whereby a sulfated neurosteroid or related molecule could act synergistically 
with direct allosteric modulation of receptor function to profoundly influence synaptic 
transmission. Such a feed-forward mechanism could provide a positive regulatory 
mechanism for the augmentation of synaptic activity independent of NMDAR channel 
activity, with downstream consequences for NMDAR dependent synaptic plasticity and 
memory.  
 Regulated trafficking of NMDARs between membrane and intracellular pools is 
critical for maintenance and plasticity of synaptic connections, and dysregulation of 
NMDAR trafficking has been implicated in neuropsychiatric disorders  (Lau and Zukin, 
2007). The present results suggest that NMDAR surface expression is subject to a novel 
mode of regulation mediated by neuroactive steroids via the NMDA receptor itself, 
which may play a role in disorders of NMDAR trafficking or provide a basis for 
development of therapeutic interventions. 
 
Respective contribution 
C. Smith: writing concerning NMDAR trafficking, graphics in figure 6,8,9,10 experiment 
planning, execution and analysis in figure 9 (in collaboration with S. Martin). 
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Supplemental Figures 
 
Supplemental Figure 1. Delayed potentiation is NMDAR specific. (A) Representative 
traces obtained from a Xenopus oocyte co-expressing NR1-1a/NR2A and !1"2#2s 
receptors show typical responses to control applications of NMDA (300 µM) or GABA 
(500 µM), and applications of NMDA + PS  and GABA + PS with or without a 
prolonged (10 min) pre-exposure to PS (100 µM). (B) Averaged peak current responses 
to NMDA + PS without (open bars) or after (solid bars) 10 min pre-exposure to PS. Vh = 
-70 mV. Responses are normalized to the response in the absence of PS (note that PS 
allosterically inhibits GABA responses but enhances NMDA responses). Statistical 
significance was assessed by 2-tail paired t-test. Error bars represent SEM. Work 
completed by E. Kostakis 
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Supplemental Figure. 2. Delayed potentiation is occluded by pretreatment with 
PMA. Response of oocytes expressing NR1-1a/NR2A receptors to 300 µM NMDA is 
potentiated by treatment with PMA (2 µM, 10 min). PMA-treated oocytes exhibit rapid 
potentiation by PregS, but delayed potentiation is absent. Left, vehicle treated oocytes, 
right, PMA treated (note difference in scale). Mean peak NMDA induced currents are 
expressed relative to the NMDA response prior to treatment with PMA and/or PregS. 
Error bars indicate s.e.m. Number of oocytes tested was 7 (vehicle) and 8 (PMA). # 
Significantly different from control. * Significantly different from simultaneous addition 
of NMDA and PregS (p < 0.001, paired 2-tail t-test). Work completed by E. Kostakis 
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Chapter 3 
Pregnenolone Sulfate at Picomolar Concentrations Causes Intracellular Calcium 
Rise and CREB Phosphorylation via Synaptic NMDA Receptors in Primary Rat 
Cortical Neurons3 
 
Abstract 
 PregS is a neuroactive steroid derived from cholesterol that augments LTP in 
rodent hippocampal slices, improves performance in active and passive avoidance tests 
for mice and novel-arm exploration in a Y-maze. In mice, it also ameliorates memory 
deficits induced by intracerebroventricular infusion of aggregated "-25-35 amyloid 
peptide in mice.  We have shown previously that PregS increases striatal dopamine (DA) 
overflow and synaptic DA release via an N-methyl-D-aspartate receptor (NMDAR) 
dependent manner using in vivo microdialysis and synaptosome superfusion, 
respectively.   Additionally, we observed that at micromolar concentration PregS induces 
an increase in neuronal intracellular calcium concentration ([Ca2+]i) and the surface 
expression of NMDAR in cortical neurons.  As PregS has been detected in brain at bulk 
concentrations of 0.1 nM to 5 nM, we asked whether low, picomolar concentrations of 
PregS might alter [Ca2+]i.  We find that PregS increases [Ca2+]i with an EC50 of 2pM and 
stimulates CREB phosphorylation, both of which depend upon synaptic activity and 
synaptic (but not extrasynaptic) NMDARs.  The novel high potency effect of PregS in 
neurons is consistent with an endogenous role for sulfated neurosteroid modulation of 
                                                
3 Smith, CC, Russek, SJ, Gibbs, TT, Farb, DH (In Preparation) 
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synaptic transmission. Additionally, high affinity PregS activation of CREB, a 
transcriptional activator implicated in both long and short forms of memory, may provide 
a novel platform for the therapeutic treatment of disorders that can be improved via the 
modulation of neural networks. 
 
Introduction 
 Many neurological disorders such as Alzheimer's disease, depression, Parkinson's 
disease, and schizophrenia exhibit symptoms associated with deficits in learning and 
memory (Lee 2009). There is currently an unmet medical need for cognitive enhancers 
with efficacy across the spectrum of neurological disorders associated with learning and 
memory impairment. Negative symptoms of schizophrenia such as cognitive deficits are 
currently not managed by antipsychotic antidopaminergic treatments, and are correlated 
with poor clinical outcomes (Milev 2005).  Positive modulation of NMDARs is 
considered to be a potential mechanism for cognitive enhancer action/discovery (Bibb 
2010). Options for pharmacological enhancement of NMDAR function are currently 
limited, yet some clinical studies report benefits from treatment of schizophrenic patients 
with agonists acting at the NMDAR glycine coagonist site (Labrie 2009), while other 
studies find no clinical benefit (Buchanan 2007).  Preclinical results suggest that 
NMDAR modulators are promising candidates for cognition enhancement therapeutics 
(Collingridge 2013) 
 One such candidate is a neurosteroid, PregS, a subtype-selective NMDAR 
positive allosteric modulator (Wu 1991; Malayev 2002).  Neurosteroids are steroids that 
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are synthesized from cholesterol in the central nervous system independently of the 
endocrine system (Baulieu 1997; Baulieu 2001). Steroids are capable of affecting a 
diverse range of cellular functions by binding to cytosolic and nuclear receptors that bind 
to DNA and induce changes in gene transcription (Kawata 2008; Marques 2009).  
However, neurosteroids are also capable of  modulating neurotransmission by non-
genomic mechanisms (Gibbs 2006). PregS modulates synaptic transmission by both 
presynaptic and postsynaptic mechanisms across multiple neurotransmitter systems 
(Zheng 2009). PregS modulates NMDA, glycine, and GABAA receptors and acts as an 
agonist of Ca2+ permeable TRP channels, all with micromolar potency (Wu 1991; Park-
Chung 1997; Wagner 2008).  PregS also exhibits a higher potency mode of action by 
inducing neurotransmitter release in rat striatum (Sadri-Vikili 2008; Whittaker 2008).  
PregS potentiates synaptic LTP and enhances spatial memory in rat behavioral tests 
(Sliwinski 2004; Flood 1995), and inhibition of steroid sulfatase ameliorates deficits in 
spatial memory induced by septal-hippocampal lesions (Babalola 2012).  Conversion of 
the precursor PREG to PregS may in part underlie PREG efficacy in ameliorating 
cognitive deficits in schizophrenia (Marx 2009).  
  PregS is subtype-selective for NMDARs (positive modulation of NMDARs 
containing NR2A and NR2B, negative modulation of NR2C and NR2D containing 
NMDARs) at micromolar concentrations (Malayev 2002).  We previously documented 
pM - nM, NMDAR-dependent effects of PregS on dopamine release in the striatum 
(Sadri-Vakili 2008; Whittaker 2008). Results from our lab show that PregS modulates 
NMDAR receptor trafficking in oocytes and cortical neurons in culture in an NMDAR-
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contingent and Ca2+-dependent manner. This occurs with greater potency than modulation 
of NMDAR 'fast' (msec) transmission (100nM vs. EC50~60µM, respectively). (Kostakis, 
2013).  PregS activation of NMDARs ion and subsequent initiation of Ca2+-meditated 
signaling may mediate long term changes in synaptic function. Nanomolar concentrations 
of PregS enhances CA1 LTP in rat hippocampal slices in a manner that correlates with its 
potentiation of NMDARs (Sliwinski 2004). Additionally, PregS induced LTP of 
perforant path-dentate granule cells is NMDAR dependent and NR2-subtype specific. 
Such LTP correlates with increased [Ca2+]i and phosphorylation of the transcription 
factor CREB (pCREB) (Chen 2007). PregS induced pCREB activation and potentiation 
of LTP also requires activation of extracellular signal related kinase 2 (ERK2)(Chen 
2007). In fact, evidence supports a functional link between PregS activation of 
NMDARs, increase in [Ca2+]i, ERK activation and subsequent production of pCREB.  
ERK1 and ERK2 (commonly referred to as ERK1/2) and ERK3 are members of the 
mitogen-activated protein kinase (MAPK) superfamily of serine/threonine kinases. This 
group of kinases forms a signaling cascade whose role can be described as cellular 
membrane input integration and transduction (Pearson 2001).  MAPKs can be activated 
by protein receptor kinases as well as calcium influx resulting from membrane 
depolarization and ion channel activation (Thomas 2004). A well described MAPK 
pathway that includes ERK1/2 is diagrammed in Fig. 1a (Pearson 2001). Stimuli that 
increase Ras-GTP levels activates the protein kinase Raf, which activates the enzyme 
MAPK/ERK kinase (MEK). MEK then phosphorylates ERK1 and ERK2 (also known as 
p44 and p42 MAPK) (Thomas 2004). MEK inhibition blocks ERK activity and LTP 
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induction in area CA1 in rat hippocampal slices (English 1997), mediates AMPAR 
surface insertion and removal (Zhu 2002) and also blocks behavioral measures of 
learning and memory (Selcher 2002).  The potential role of ERK in mediating LTP is 
diagrammed in Fig.1b. 
 NMDA receptors are coupled to the ERK pathway via a direct association 
between the Ras-guanine-nucleotide-releasing factor (RasGRF1) and the NR2B (and not 
NR2A or NR1) subunit (Krapivinsky 2003).  NMDAR activation and localized increase 
in [Ca2+]i stimulates ERK1/2 activation and prolongs the formation of pCREB following 
synaptic stimulation (Hardingham 2001), while MAP kinase inhibition also blocks the 
late phase of pCREB activation that follows a strong (90mM K+) depolarization (Wu 
2001). CREB is a member of the bZIP family of transcription factors as it contains a 
leucine zipper domain that allows both homo and hetero- dimerization between members 
of the CREB family and a C-terminal basic domain that binds to cis-regulatory elements 
(CRE) on DNA (Lonze 2002). There are a large number of genes with CRE promoters, 
notably, neuronal nitric oxide synthase (nNOS), brain-derived neurotrophic factor 
(BDNF) and presenilin (West 2002). CREB also contains a kinase-inducible domain 
(KID) that has a serine residue at position 133 (Ser133). This residue is phosphorylated in 
response to extracellular stimuli. Deletion of the Ser133-containing KID domain 
diminishes the CREB response to stimuli and expression of a KID domain (with no other 
CREB domains) is sufficient to activate gene transcription in response to specific cell 
signals (Shaywitz 1999).  There are a multitude of kinases that can phosphorylate Ser133 
including Ca2+/calmodulin-dependent kinases (CaMK) I, II, IV, ribosomal protein SG 
  
 76 
A.         B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11. A MAPK signaling pathway (adapted from Thomas et al., 2004). A) Ca2+ influx 
through NMDARs or VGCCs activates Ras-GTP to stimulate Raf phosphorylation of 
MEK, which then phosphorylates ERK.  Following its activation ERK translocates to the 
nucleus and phosphorylates its substrates, which may include CREB. B) NMDAR 
stimulation as would commonly be used in LTP induction protocols stimulates the 
MAPK pathway, and is blocked by MEK inhibitors PD98059, U0126 and SL327.   
NMDAR VGCC 
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kinase of 90kDa (RSK)1 - 3, protein kinase C (PKC), and protein kinase A (PKA) 
(Shaywitz 1999). The convergence of multiple signaling pathways for CREB activation 
places CREB at the nexus of synaptic activity, indicating that it serves as a downstream 
integrator of neuronal responses (West 2002), and in particular, neuronal Ca2+ signaling 
(Bito 1996).  
 Synaptic strength (the likelihood of post-synaptic activation following presynaptic 
activation) and its enhancement has been associated with an increase in measures of 
learning and memory (Alberini 1995). Long term changes in synaptic strength and 
memory depend on transcription factor-mediated mRNA and protein synthesis (Frey 
1988; Frey 1996).  CREB is required for long-term facilitation in Aplysia (Alberini 1995) 
and drosophila (Yin 1994). Deletion of exon 2 of CREB in a mouse transgenic model 
eliminates late phase LTP and results in deficits in contextual fear conditioning and 
spatial memory performance (Bourtchuladze 1994). The induction of LTP in organotypic 
cultures (Leutgeb 2005) and in brain slices (Ahmed 2005) correlates with increased 
CREB phosphorylation. Additionally, constitutively active CREB expressed in the 
hippocampal CA1 and dentate gyrus region facilitates late-phase LTP in mouse 
hippocampal slices (Barco 2002). In summary, CREB activation is both necessary and 
sufficient for the maintenance of synaptic potentiation.  
 We hypothesize that PregS increases [Ca2+]i with pM - nM potency via an 
NMDAR dependent mechanism.  In this report we show that PregS induces an increase 
in [Ca2+]i  primary cultured cortical neurons with high affinity that requires glutamatergic 
synaptic transmission. We also demonstrate that pM PregS activates CREB, a 
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transcription factor critical in the maintenance of LTP (Bourtchuladze 1994; Leutgeb 
2005; Ahmed 2005; Barco 2002).  Taken together, our results indicate that novel PregS 
responses in neurons can display high potency, and be contingent upon the activation of 
synaptic rather than extrasynaptic NMDARs.  We believe that these new observations 
may position PregS as a potent endogenous regulator of neurotransmission and provide a 
useful platform for the development of high-affinity small molecules as cognitive 
enhancers. 
 
Methods 
Cell Culture: Embryonic (E18) rat cortical cells were isolated and cultured as in (Russek 
2000) for 6-8 days in vitro. 
Western blot: Primary cortical cells plated on poly-L-lysinated (0.1mg/ml) 100mm dishes 
(Nunc) were treated with steroid drug solutions for 10 min at 37°C, rinsed once and 
harvested in ice-cold 1xPBS, pH 7.2 supplemented with cOmplete protease inhibitor 
cocktail and PhosStop phosphatase inhibitor cocktail (Roche, IN) and 1mM PMSF.  
Whole cell extracts were prepared in lysis buffer (in mM) Tris-HCl 500, pH 7.4, NaCl 
1500, 2.5% deoxycholic acid, 10% NP-40, EDTA 10, PMSF 1, Na3VO4 1, NaF 1, 
supplemented with cOmplete protease and PhosStop phosphatase inhibitor cocktails. 
Proteins were resolved under reducing conditions (100mM DTT) using SDS-PAGE and 
transferred to nitrocellulose membranes (Invitrogen, CA). Membranes were incubated in 
anti-sera raised against phospho-CREB or CREB (both 1:1000; Cell Signaling, MA) 
followed by incubation in HRP-conjugated secondary antibody (1:2000; Santa Cruz 
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Biotechnology, CA). Blots were stripped and incubated in anti-sera raised against "-actin 
(1:30,000; Sigma-Aldrich, MO) followed by incubation in peroxidase-conjugated 
secondary antibody (1:15,000; Vector Laboratories, CA) and visualized using ECL-plus 
(GE Healthcare, WI).  
Confocal Ca2+ imaging:   Primary cortical cells kept in monolayer culture were incubated 
for 30 minutes at 37°C with the cell membrane-permeable Ca2+ indicator Fluo-4 
acetoxymethyl ester (Invitrogen, CA). To follow the changes in [Ca2+]i , fluorescence 
intensity (F) was measured at excitation wavelength of 488nm and emission of 505-
735nm, and normalized to initial intensity (F/F0, arbitrary units) for each region of 
interest. The cells were imaged in real time at room temperature in extracellular buffer (in 
mM) NaCl 137, KCl 5, CaCl2 3, glucose 25, HEPES 10.  A Zeiss Laser Scanning 
Microscope (LSM) was used with 40x water immersion objective, and images were 
captured at 1 frame per 1.57 sec. Regions of interest were selected for morphologically 
identified cells using Zeiss Axiovert software to determine changes in fluorescence 
intensity with a dynamic range of 0-255. The effect of drug application ($F/F) was 
determined as a difference between (F/F0) before and during the peak (F/F0) after drug 
application.  
Drugs: All steroids were from Steraloids (RI), prepared as stock solutions in DMSO and 
suspended in imaging buffer to a final DMSO concentration 0.05%.  D(-)-2-Amino-5-
phosphonopentanoic acid (D-AP5), ifenprodil, Mk-801, bicuculline, tetrodotoxin, 
diethylstilbesterol, KN-93, and nifedipine were from Sigma-Aldrich (MO), Ro 25-6981 
and BD 1063 were from Tocris (MO), CNQX was from Abcam Biochemicals (MA), 
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U0126 was from EMD Millipore (MA).  
 
Results 
 Our previous results demonstrate that µM concentrations of PregS increases 
[Ca2+]i in cortical neurons (Kostakis 2013).  Additionally, pM - nM PregS induces DA 
release from striato-nigral terminals an an NMDAR contingent manner (Sadri-Vakili 
2008; Whittaker 2008). If it is true that PregS modulates excitatory neurophysiological 
processes in vivo then we hypothesize that at around pM concentrations PregS will 
increase neuronal [Ca2+]i in a manner contingent upon glutamatergic synaptic 
neurotransmission. In order to test this hypothesis,  we performed Fluo-4 confocal 
imaging (Grienberger 2012).  Pharmacological antagonists were used to determine if 
activation of presynaptic action potentials, and/or the activation of synaptic NMDARs, 
AMPARs, and L-type voltage gated Ca2+ channels is required for PregS-induced changes 
in [Ca2+]i detection. 
 To our surprise, 50pM PregS induces a transient and marked elevation of 
fluorescence intensity in the soma (Fig. 12), suggesting that there is a high potency 
mechanism for elevating [Ca2+]i. We also observed 50pM PregS-induced elevations in 
[Ca2+]i in the processes and boutons located on the processes (Fig. 13), however most of 
our studies focused on [Ca2+]i changes in cell soma for consistency of the dataset.   
 A dose-response analysis was performed with concentrations of PregS ranging 
from 500fM to 5nM and it was determined that PregS induces increases in [Ca2+]i with a 
potency of 2pM (95% CI 1-5pM) (Fig. 14).  In subsequent experiments all steroids were  
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Fig. 12. Picomolar concentrations of PregS increase [Ca2+]i in primary cultured 
cortical neurons. (A) Phase-contrast (left),  fluorescence (middle) and merged (right) 
image of a field of cortical neurons loaded with Fluo-4. (B) Cortical neurons before (top, 
0 s) and after (bottom, 19 s) application of 50pM PregS. Regions of interest defined 
morphologically as cell bodies are outlined in white. (C) Mean ± SEM fluorescence 
intensity normalized to average initial intensity (F/Fo) for three regions of interest in (B). 
Scale bar, 10µm. Work completed by C. Smith and S. Martin  
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Figure 13.  50pM PregS increases [Ca2+]i in primary cortical neuronal processes and 
boutons (A) Confocal fluorescence image of a representative field of cortical cells. The 
effect of 50pM PregS (added at t = 12.6 s) on [Ca2+]i is displayed in (B) for the entire 
field of neurons shown in (A). In (C) changes in [Ca2+]i were determined along the length 
of a process, as indicated by the arrowheads in (A). Three boutons were also selected as 
indicated by the arrows (A). The changes in [Ca2+]i for these three boutons is displayed in 
(D), with each color representing a single bouton. Scale bar, 50µm.  
Work completed by C. Smith and S. Martin 
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Figure 14. PregS induces an increase in [Ca2+]i that is dose-dependent. Effect of 
PregS on levels of [Ca2+]i in monolayers of primary cultured cortical neurons. Data points 
are averaged values of baseline-subtracted peak fluorescence responses (arbitrary units) 
and are plotted as mean ± SEM. Averaged concentration-response data was fit using 
nonlinear regression. Fitted values for the concentration-response curve include EC50 = 2 
pM (indicated on the y-axis by red arrow). 95% confidence interval range: 1 - 5 pM,  Hill 
slope = 0.7± 0.2,  Emax = 0.45 ± 0.03.  (n) = number of cells tested. Work completed by 
C. Smith and S. Martin  
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tested at a concentration of 50pM, at which PregS exhibits an intermediate level of 
activity.  It is well established that neuroactive steroids (at !M concentrations) 
modulate NMDA-induced increases in [Ca2+]i levels in a manner that depends on their 
geometry and charge (Weaver 2000). B-ring saturated steroids with C3 negative or 
positive charge potentiate or reduce NMDA-induced [Ca2+]i levels, respectively, (Irwin 
1994) while the uncharged precursor to PregS (PREG) is without effect (Weaver 2000). 
We hypothesized that if the structural requirements for pM PregS-induced [Ca+2]i  
increase are similar to µM PregS modulation of NMDAR function, then pM PregS 
elevations of [Ca+2]i  will require the C3 negative charge geometry conferred by a C5-C6 
double bond. In order to test our hypothesis we selected 5 compounds that are structurally 
related to PregS but chemically and pharmacologically distinct (Fig. 15). Pregnenolone 
hemisuccinate (PregHS) is a synthetic chemical mimic of PregS with a succinate group 
substituted for the sulfate group at the C3 carbon that potentiates the NMDAR with 
decreased efficacy compared to PregS (Weaver 2000).  PregHS (50 pM) induced an 
increase in [Ca2+]i with less efficacy than PregS (**p<0.01, student's t-test), indicating that 
the chemical identity (sulfate vs. succinate) of the C3 negative charge changes the 
magnitude of the [Ca2+]i  increase (Fig. 15).  PREG is the neutral, unsulfated precursor to 
PregS and does not modulate the fast NMDA response (µM concentrations) (Kostakis 
2013). We now report that PREG (50 pM) does not increase [Ca2+]i, indicating that a 
negative charge at C3 is required for the effect, and that pM PregS-induced [Ca2+]i  
increase is not a non-specific effect of the steroid nucleus. This experimental finding also 
argues against extracellular conversion of PregS to PREG, which could then act at an 
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intracellular site to increase [Ca2+]i.  A C5-6 double bond confers a planar structure to 
PregS. Pregnanolone sulfate (PAS), a B-ring saturated neuroactive steroid has a bent 
configuration which shifts the C3 negative charge outside the plane of the ring structure, 
and at µM concentrations is a negative modulator of NMDA-induced [Ca2+]i increase 
(Irwin 1994). PAS (50 pM) also does not increase [Ca2+]i , indicating that the C5-C6 
double bond plays a role in the effect (Fig. 15). The lack of effect of B-ring saturated 
steroids was confirmed by further experiments with pregnanolone hemisuccinate (PAHS, 
50pM), a chemical mimic of PAS with a negatively charged succinate group substituted 
for the C3 sulfate, which, like PAS is a negative modulator of NMDA-induced [Ca2+]i 
increase (Weaver 2000).  As with PAS, PAHS (50pM) did not increase [Ca2+]i (Fig. 15).  
Pregnanolone (PA) the unsulfated precursor to PAS, is an NMDAR negative modulator 
(Park-Chung 1997) and a GABAAR positive modulator with nM potency (Peters 1988).  
PA had no effect on [Ca2+]i  levels (Fig. 15), while in control experiments (data not 
shown) PA did not inhibit 20mM K+ depolarization-induced [Ca2+]i increases, indicating 
that pM modulation of GABAARs with these steroids is not likely. Taken together the 
results are consistent with a binding site for pM neuroactive steroid-induced [Ca2+]i 
increase that requires a negatively charged C3 group (sulfate > succinate) that is 
restricted to a planar orientation by an unsaturated B-ring. 
 Our previous published results demonstrated that NMDARs are critical for pM - 
nM PregS-induced DA release from nigro-striatal terminals, therefore we hypothesized 
that if picomolar PS induces [Ca2+]i increases, the response will depend on excitatory  
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Fig. 15. Neuroactive steroids affect [Ca2+]i in a structure-specific manner.  (A) All 
compounds shown were tested at 50pM.  Comparison with one-way ANOVA revealed a 
p<0.0001 between all groups. Pair-wise comparisons were performed with students t-test 
(***p<0.0001, **p<0.01,  (n.s.) not significant p > 0.05). There was no difference 
between PREG, PA, PAHS and PAS (p > 0.05, not shown). (n) = number of cells tested. 
(B)  Chemical structures of steroid compounds in study. Abbreviations: pregnenolone 
sulfate (PregS), pregnenolone hemisuccinate (PHS), pregnenolone (PREG), pregnanolone 
sulfate (PAS), pregnanolone hemisuccinate (PAHS), pregnanolone (PA).  Work 
completed by C. Smith and S. Martin  
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neurotransmission mediated by NMDARs. In order to test this hypothesis we first 
eliminated excitatory neurotransmission by inhibiting action potentials using tetrodotoxin 
(TTX, 1µM) to block voltage-gated Na+ channels (Romano-silva 1994; Colbert 1996). 
Preincubation of the cultures with TTX for 30 min prior to PregS application eliminated 
PregS-induced [Ca2+]i increase (p < 0.001 PregS vs. TTX+PS, Tukey's multiple 
comparison test) demonstrating that this effect is action potential-dependent and likely 
requires synaptic transmission (Fig. 16a). This result also suggests that PregS is not  
inducing a direct elevation of presynaptic [Ca2+]i to induce glutamate release, as such an 
event would not be blocked by TTX. 
 L-type voltage gated Ca2+ channels (Ca2+L) are known to be activated by action 
potential stimuli (Helton 2005). The requirement for action potentials in the pM PregS 
effect led us to hypothesize that if pM PregS induced [Ca2+]i increases requires 
glutamatergic depolarization of the post-synaptic membrane then inhibition of Ca2+L 
should block the pM PregS effect. In order to test this hypothesis we used nifedipine to 
block Ca2+L (ffrench-Mullen 1994; Helton 2005). While nifedipine increases [Ca2+]i 
slightly, it completely eliminates the 50pM PregS induced [Ca2+]i increase (p < 0.001, 
PregS vs. nifedipine+PregS, Tukey's multiple comparison test).  These results indicate 
that the 50pM PregS effect is dependent on Ca2+L  activation (Fig. 16b), and is consistent 
with a requirement of post-synaptic membrane depolarization that is dependent on 
synaptic activity. 
 Based on the requirement for Ca2+L , if post-synaptic membrane depolarization and 
subsequent VGCC activation by NMDARs (Dingledine 1999) is  required for PregS- 
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Fig. 16. 50pM PregS-induced [Ca2+]i increase requires presynaptic action potentials, 
Ca2+L  and NMDAR activation. (A) 50pM PregS-induced [Ca2+]i increase is inhibited by 
tetrodotoxin. Primary cortical cultures were pretreated with the sodium channel blocker 
tetrodotoxin (TTX, 1µM) or control for 30 min prior to acute application of 50pM PregS 
± TTX. (B) 50pM PregS-induced [Ca2+]i increase is blocked by the Ca2+L inhibitor 
nifedipine (10µM). (C) D-AP5 (100 µM) inhibits 50pM PregS-induced [Ca2+]i rise. See 
results text for additional NR2B subtype-specific antagonist results. (D) PregS-induced 
[Ca2+]i increase is partially inhibited in the presence of 2.5µM CNQX. Comparison with 
one-way ANOVA revealed a p<0.001 between all groups tested. Post-hoc analysis was 
performed with Tukey's multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001). 
(n) = number of cells tested Work completed by C. Smith and S. Martin  
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induced [Ca2+]i rise, then NMDAR inhibition will block this effect. In order to determine 
the role of NMDAR activation in PregS effect on [Ca2+]i we used D-AP5, a competitive 
NMDA antagonist (Berman 1997)  We found that the PregS effect is inhibited by D-AP5 
(100 µM) (p < 0.001, PregS vs. DAP5+PregS, Tukey's multiple comparison test) and 
therefore requires NMDA receptor activity (Fig. 16c).  NMDARs are under Mg2+ block at 
rest and require membrane depolarization for the channel pore to become ion permeable 
(Dingledine 1999), so we hypothesized that pM concentrations of PregS may induce 
membrane depolarization via AMPAR activation prior to NMDAR activation, and that an 
AMPAR antagonist will inhibit the effect. In order to determine the role of AMPA 
receptor activation in PregS-induced [Ca+2]i increases we utilized the AMPA receptor 
blocker CNQX (2.5µM) (Itazawa 1997).  AMPA receptor block partially reduces the 
effect  (p < 0.01, PregS vs. CNQX+PregS, Tukey's multiple comparison test) (Fig. 16d). 
The failure of CNQX to completely block the effect  indicates that membrane 
depolarization by AMPARs is not an absolute requirement for NMDAR and Ca2+L -
mediated PregS-induced increases in [Ca+2]i. There may be an incomplete Mg2+ block of 
NMDARs under our experimental conditions, or contribution by an additional ion 
channel activated by PregS.  Additionally, if there is ongoing synaptic activity and 
glutamate release in our cultures then we would expect there to be a sub-population of 
NMDARs that were already activated at the time of CNQX administration, and thus 
capable of potentiation by PregS. 
 PregS potentiates the NMDA response of NR2A and NR2B-containing NMDARs 
exogenously expressed in oocytes (Malayev 2002) with µM potency. Additionally, PregS 
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at nM concentrations enhances binding of the NR2B-selective antagonist ifenprodil in 
CHO cells exogenously expressing NR1/NR2B receptors or in rat frontal cortex 
(Johansson 2005, 2008). If it is true that low pM PregS is similarly subtype selective for 
NR2B then we hypothesized that elevations in [Ca2+]i caused by PregS will be inhibited 
by blocking only NR2B-containing NMDARs. Indeed, we verified that the NR2B-
specific antagonists ifenprodil (1nM) (Williams 1995) and Ro 25-6981 (1µM) (Fisher 
1997) block PregS [Ca+2]i increases (PregS vs ifenprodil + PregS p <0.001, PregS vs. Ro 
25-6981 + PregS p < 0.001 (Results not shown).  Ro 25-6981 inhibited the effect  with 
IC50 = 3µM, 95% CI 0.2 - 49 µM (Fig. 17) within the range of Ro 25-6981 inhibition of 
NR2B-containing NMDARs (Fisher 1997).  In contrast, ifenprodil antagonizes an 
unexpectedly high affinity (250pM) inhibition of PregS-induced [Ca2+]i increases.  We 
reasoned that based on the dose-response curve we obtained for pM PregS elevations of 
[Ca2+]i , if ifenprodil is selectively interacting with a high affinity PregS binding site then 
pM ifenprodil will inhibit pM PregS in a dose dependent manner. Additionally, we 
hypothesized that the high affinity interaction with the pM PregS site would be specific to 
ifenprodil chemical structure and not solely due to NR2B inhibition.  In order to test this 
hypothesis we generated a dose-response curve of ifenprodil inhibition and compared it 
to Ro 25-6981 inhibition of the PregS effect, using ifenprodil inhibition of 20uM 
NMDA-induced [Ca2+]i  increase as a control (Fig. 17). We determined that ifenprodil 
inhibits PregS-induced [Ca2+]i increases with an IC50 of 10pM (95% CI 6-17pM) while 
Ro-256981 inhibits PregS-induced [Ca2+]i increases with an IC50 of 3µM (95% CI 0.2-
49mM), a 5-orders of magnitude difference in potency (Table 6). Ifenprodil inhibits 
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20µM NMDA-induced [Ca2+]i increases with an IC50 of 524 nM (95% CI 82 nM - 3350 
nM). The concentration of ifenprodil that inhibits NMDA-induced [Ca2+]i increases  is in 
line with previous findings (Church 1994). The difference in potency between ifenprodil 
inhibition of 50pM PregS vs. NMDA-induced [Ca2+]i increases is consistent with a 
possible direct interaction with the pM PregS binding site, indicating a potential novel 
site of action for high affinity ifenprodil recognition in neurons.  
 Previous literature has suggested a role for the sigma receptor ($R) in PregS 
augmentation of LTP (Sabeti 2007). In order to assess the role of $Rs in the high affinity 
PregS effect on [Ca2+]i  we tested the sigma receptor subtype 1 antagonist BD1063 (1µM) 
(Matsumoto 1995) for its ability to inhibit the PregS effect. BD1063 alone has no effect 
on [Ca2+]i levels and does not inhibit 50 pM PregS-induced [Ca2+]i  increases (p = 0.2, 
PregS vs. BD1063+PregS, Tukey's multiple comparison test) (Fig. 18a), and therefore 
sigma receptors are likely not involved in the pM PregS response. 
 In order to test a possible involvement of store-operated calcium channels 
(SOCC) in propagating [Ca2+]i  increases induced by 50pM PregS, primary cortical 
cultures were preincubated for 30 min in 100nM diethylstilbesterol (DES) to block 
SOCCs (Zhakarov et al., 2004). DES did not block PregS-induced [Ca2+]i  increases (p = 
0.1 PregS vs. DES+PregS, Tukey's multiple comparison test), ruling out their 
involvement in the response (Fig. 18b).   
 Increases in [Ca2+]i  in neurons initiates a signal transduction cascade that leads to 
the activation of the transcription factor CREB protein via phosphorylation of a key
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Figure 17. Ifenprodil displays high potency inhibition of PregS induced [Ca2+]i 
increase.  The dose-inhibition curve for 50pM PregS in the presence of ifenprodil or  
Ro-256981. Results are normalized to controls for PregS (50pM) or NMDA (20µM) in 
the absence of antagonist and fit using nonlinear regression.  
Work completed by C. Smith and S. Martin 
 
 
 
Table 5. Parameters of nonlinear regression curve fits from Fig.17.  50pM PregS- 
[Ca2+]i increase is inhibited by the NR2B-subunit selective antagonists ifenprodil (IFEN) 
and Ro-256981, with ifenprodil displaying 5-fold greater inhibitory potency. 
Lower Upper Mean SEM 
20uM NMDA IFEN 5.2E-07 8.2E-08 3.4E-06 -0.56 0.28
50pM PregS IFEN 7.6E-12 4.3E-12 1.4E-11 -2.2 1.6
50pM PregS Ro256981 3.1E-06 2.0E-07 4.9E-05 -0.81 0.74
Agonist Antagonist IC50 (M)
IC50 95% CI (M) Hill Slope
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Fig. 18. PregS-induced [Ca2+]i increase is insensitive to inhibition of sigma receptors 
and store-operated Ca2+ channels (A) PregS-induced [Ca2+]i increase is not inhibited by 
the sigma receptor antagonist BD1063 (1!M) (n.s. p = 0.26), nor (B) the store operated 
Ca2+ channel inhibitor diethylstilbesterol (DES, 100nM) (n.s. p = 0.1). Comparison with 
one-way ANOVA revealed a p<0.001 between experimental groups tested. Post-hoc 
analysis was performed with Tukey's multiple comparison test. (n) = number of cells 
tested. Work completed by C. Smith 
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residue at serine 133 to produce phospho-CREB (pCREB) (Hardingham 2001).  It is also 
known that Ca+2 influx via Ca2+L induces pCREB (Shaywitz 1999), and we have 
demonstrated that 50pM PregS induced [Ca2+]i increase requires Ca2+L and the 
contribution of action potentials, AMPARs and NMDARs.   
 We next hypothesized that if PregS induced [Ca2+]i is indicative of a 
neurophysiological response involving  L-type VGCCs  then low pM PregS will activate 
the transcription factor CREB in a similarly NMDAR dependent manner.  In order to 
determine if PregS induces pCREB we treated cortical cells with 50pM PregS (control: 
0.05% DMSO) and quantified changes in pCREB by separation of proteins from whole 
cell extracts by SDS-PAGE followed by immunodetection using antisera specific for 
CREB or pCREB (detection was performed using enhanced chemiluminescence).  
Changes in the ratio of pCREB / CREB were quantitated by western blot analysis. It was 
determined  that 50pM PregS induces a 44 ± 13% increase in the ratio of pCREB to total 
CREB (p < 0.01, Student's unpaired t-test), (Fig. 19), confirming that low pM PregS 
induces pCREB, an activated transcription factor that is critical for long term changes in 
synaptic plasticity (Shaywitz 1999). 
 As our results described above for PregS induced [Ca2+]i increases (Fig. 14) 
demonstrate the response requires a negative charge at C3 and a C5-6 double bond, we 
hypothesized that the would also display a similar profile of dependence.  In order to 
determine the requirement a C5-6 double bond we tested PAS, which has a saturated B-
ring instead of a C5-6 double bond. PAS did not increase pCREB/CREB (p = 0.5, 
Tukey's multiple comparison test), confirming the requirement of a C5-6 double bond  
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Fig. 19. 50pM PregS increases phospho-CREB. (A) 50pM PregS increases phospho-
CREB immunoreactivity as a proportion of total CREB. Cultured cortical cells were 
treated with 0.05% DMSO (veh) or steroids (all 50pM) for 10 min at 37°C. Proteins were 
separated by SDS-PAGE followed by immunoblot with antibodies raised against 
phospho-CREB or CREB.  (B) 50pM PregS induces a 44 ± 13 % increase in the ratio of 
phospho-CREB to CREB (blots were quantified by densitometry, normalized to b-actin 
loading controls and pCREB/CREB intensity ratios were compared to vehicle controls). 
Pair-wise comparisons were performed with students t-test (**p < 0.01). N=number of 
independent cultures. Work completed by C. Smith and S. Martin 
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in the pM PregS induced pCREB effect. The synthetic mimetic of PAS, pregnanolone 
hemisuccinate (PAHS) also had no effect on levels of pCREB. Also tested was 
dehydroepiandrosterone sulfate (DHEAS), which differs from PregS by a 17-C acetyl 
group instead of a 17-C carbonyl group, but retains a double bond at C5-6 and a 
negatively charged C3 sulfate group. Surprisingly, DHEAS had no effect on 
pCREB/CREB (p = 0.6, Tukey's multiple comparison test) (Fig. 20). As a control for 
DHEAS, dehydroepindrosterone (DHEA) did not increase pCREB levels. This result 
indicates that while B-ring saturation is required, a C3 negative charge alone is not 
sufficient to confer pM neuroactive steroid-pCREB activity, and that additional structural 
constraints such as the length of the C-17 group may also play a role in 50pM PregS 
activation of pCREB.   
 In neurons, there are numerous signal transduction pathways that lead to CREB 
activation, one of which is the MAPK signaling pathway (Shaywitz 1999). The MAPK 
pathway is activated by the NMDA receptor or by Ca+2 influx through Ca2+L (Thomas 
2004), therefore we hypothesize that if activation of the MAPK pathway by either the 
NMDAR or Ca2+L is occurring during pM PregS application, blockade of the MAPK 
pathway would eliminate pM PregS increases in pCREB levels. In order to determine if 
50pM PregS activates the MAPK pathway primary cortical neurons were treated as 
described above and western blot analysis was performed using anti-sera specific for 
ERK or pERK.  It was determined that 50pM PregS induces a 42 ± 12% increase (p = 
0.04, Student's t-test) in the ratio of phospho-ERK (pERK) to total ERK (Fig. 12), 
indicating that 50pM PregS is sufficient to activate pERK. If activation of pERK by   
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Fig. 20. Structural specificity of sulfated steroid pCREB induction. (A) Cortical 
cultures were treated with steroids as indicated, all at 50pM concentration. Of steroids 
tested, only PregS and PHS increased pCREB. Comparison with one-way ANOVA 
revealed a p < 0.05 between all groups tested. Post-hoc test were performed with Tukey's 
multiple comparison test (*p < 0.05 vs. VEH, **p < 0.01 vs. VEH, #p < 0.01 vs. PregS). 
(n) = number of independent cultures.  (B)  Chemical structures of steroid compounds 
tested. Abbreviations used: pregnenolone sulfate (PregS), pregnenolone hemisuccinate 
(PregHS), pregnanolone sulfate (PAS), pregnanolone hemisuccinate (PAHS), 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS).  Work 
completed by C. Smith 
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A       B  
         
 
Fig. 21. 50pM PregS increases phospho-ERK (A) Cortical cultures were treated for 10 
min with 50pM PS or 0.05% DMSO (VEH). (B)  50pM PregS induces a 42 ± 12% 
increase in phospho-ERK (pERK). pERK band intensity was normalized to total ERK 
intensity and quantified as percent DMSO-treated control.  Pair-wise comparisons were 
performed with students t-test  (*p < 0.05). (n) = number of independent cultures. Work 
completed by C. Smith 
  
 99 
 
A        B 
 
   
 
 
Fig. 22. MEK inhibition blocks PregS induced pCREB. (A) Pretreatment for 30 min 
with the MEK1/MEK2 inhibitor U0126 (20µM) prevents 50pM PregS induced pCREB 
increases.  (B)  Comparison with one-way ANOVA revealed a p < 0.05 between all 
groups tested. Post hoc tests were performed with Tukey's multiple comparison test (*p < 
0.05, **p < 0.01). (n) = number of independent cultures. 
Work completed by C. Smith 
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pM PregS is sufficient to increase pCREB, then we hypothesize that PregS-induced 
pCREB occurs via the MAPK pathway and that inhibition of pERK production will 
eliminate pM PregS induced pCREB increases. In order to determine if the PregS-effect 
on pCREB requires ERK phosphorylation we utilized a MEK inhibitor (U0126, 20µM) 
(Favata 1998) to block MEK signaling. We determined that MEK inhibition blocks 50pM 
PregS induced pCREB (p < 0.01, PregS vs. U0126+PS, Tukey's multiple comparison 
test) (Fig 22). Alternatively, activation of glutamate receptors can lead to calmodulin 
(CaM) activation (Bading and Greenberg, 1999) and subsequent CamKII mediated 
phosphorylation of CREB (reviewed in Fukunaga 2000). However, the CaMKII inhibitor 
KN93 (0.25µM) (Sumi et al., 1991) did not abolish PregS-induced increases in pCREB 
(PregS vs. KN93 + PregS p >0.05) (Fig. 23), indicating that PregS activation of pCREB 
acts through a CaMKII-independent pathway. Together, these results indicate that 50pM 
PregS activation of the MAPK signaling pathway is required for 50pM PregS elevation 
of pCREB levels.  
 If a physiological consequence of pM PregS-induced [Ca2+]i increase is pCREB 
activation, then the phenomenon should also depend on excitatory neurotransmission.  In 
order to determine if PregS-induced pCREB increases are dependent on action potentials 
(as is the effect fo pM PregS on [Ca2+]i levels) we used tetrodotoxin (TTX, 1µM) to block 
Na+ channels (Colbert 1996). Preincubation of the cultures with TTX for 30 min prior to 
PregS application eliminates PregS induced elevations of pCREB (p < 0.01, PregS vs. 
TTX+PregS, Tukey's multiple comparison test) (Fig. 24).  The involvement of voltage 
gated sodium channels is consistent with a requirement for excitatory neurotransmission 
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Fig. 23. KN93 does not inhibit 50pM PregS induced pCREB. (A) CaMKII was 
inhibited by 30 min pretreatment (KN93, 250nM). (B) KN93 pretreatment does not 
inhibit 50pM PregS induced increase in pCREB/CREB ratio, and has no effect on basal 
pCREB/CREB. Comparison with one-way ANOVA revealed a  p < 0.05 between all 
groups tested. Pair-wise comparisons were performed with students t-test. **p < 0.01 
(n)=number of independent cultures.  
Work completed by C. Smith 
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Fig. 24.  Inhibition of presynaptic action potentials blocks 50pM PregS induced 
pCREB (A) Cortical cultures were pretreated with the sodium channel blocker 
tetrodotoxin (TTX, 1µM) or control for 30 min prior to a 10 min application of 50pM PS 
± TTX. (B)  Inhibition of action potentials by TTX eliminates PregS induced pCREB. 
Comparison with one-way ANOVA revealed a p < 0.05 between all groups tested. Post 
hoc tests were performed using Tukey's multiple comparison test (*p < 0.05, **p < 0.01).  
(n) = number of independent cultures.  
Work completed by C. Smith 
  
 103 
 
Fig. 25. NMDA receptor antagonists increase pCREB.  D-(-)-2-Amino-5-
phosphonopentanoic acid (DAP5, 100µM) increases pCREB and does not block PS-
induced pCREB. The NMDA receptor NR2B subunit-selective antagonist ifenprodil 
(IFEN, 250 pM) does not block PS-induced pCREB. The IFEN alone group effect on 
pCREB was not statistically different from control or PregS. Comparison with one-way 
ANOVA revealed a difference between all groups tested (p = 0.004). Pair-wise 
comparisons were performed with Student's unpaired t-test (*p < 0.05 vs. control; DAP5 
vs. DAP5+PregS p = 0.5; IFEN vs. IFEN+PregS p = 0.3). (n) = number of independent 
cultures.  Work completed by C. Smith 
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Fig. 26.  Synaptic NMDAR blockade prevents 50pM PregS activation of CREB.  
(A) Synaptic NMDA receptors were inhibited by application of bicuculline (BIC, 50µM) 
and MK801 (10µM).  (B)  MK801/BIC treatment inhibits 50pM PregS induced increases 
in the pCREB/CREB ratio, and has no effect on basal pCREB/CREB. Comparison with 
one-way ANOVA revealed a p < 0.05 between all groups tested. Pair-wise comparisons 
were performed with students t-test. *p < 0.05 (n) = number of independent cultures. 
Work completed by C. Smith 
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 In order to test the dependence of PregS-induced pCREB on NMDAR activation 
we first tested D-AP5 (100µM) and then ifenprodil (0.25nM) co-application with PregS, 
however we found that D-AP5 alone elevated pCREB levels, and ifenprodil did not 
inhibit PS induced pCREB increases (p =0.5 PregS vs. DAP5+PregS, p = 0.3 PregS vs. 
PregS+IFEN, Student's t-test) (Fig. 25).  These results were surprising given the known 
role of synaptic NMDARs in CREB phosphorylation.  However, [Ca+2]i levels and CREB 
phosphorylation are differentially regulated  by synaptic and  extrasynaptic NMDARs 
(Hardingham 2002; Liu 2007; Stanika 2009). Synaptic NMDAR activation leads to 
increased pCREB, whereas extrasynaptic NMDAR activation leads to pCREB 
dephosphorylation (Hardingham 2000). We hypothesized that if extrasynaptic NMDAR 
dephosphorylation of pCREB is the dominant pathway, blockade of both synaptic and 
extrasynaptic NMDARs will result in a disinhibition of CREB phosphorylation, therefore 
selective blockade of synaptic NMDARs should block PregS induced pCREB increases 
while avoiding extrasynaptic NMDAR-mediated disinhibition of pCREB activation. Prior 
to PregS application, GABAARs were blocked using bicuculline (BIC, 50µM), which 
induces synaptic glutamate release. The activated NMDARs were blocked with MK801 
(10µM), leaving only extrasynaptic NMDARs activatable (Hardingham 2002).  We 
determined that synaptic NMDAR inhibition attenuates the effect of 50pM PregS on 
pCREB, but has no effect on the basal pCREB/CREB ratio (p>0.05, PregS vs. 
Mk801/BIC + PregS, Student's t-test) (Fig. 26), indicating that PregS induced elevations 
of pCREB is contingent upon synaptic and not extrasynaptic NMDARs. 
 The results are summarized in a schematic in Fig. 27, in which pM PregS induced  
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Figure 27. Schematic illustrating pathways that may underlie pM PregS induced 
[Ca2+]i  and pCREB increases.   Diagram illustrates the proposed pathways that 
participate in PregS stimulated increase in [Ca2+]i  and pCREB via excitatory synaptic 
transmission in a synaptic NMDAR-dependent manner. Inhibitors used in the study are in 
bold. *KN93 did not inhibit PregS-induced pCREB increases.   
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[Ca2+]i increase in contingent upon presynaptic action potentials, Ca2+L and NMDARs, 
while pM PregS induced pCREB increase requires synaptic NMDARs, ERK activation, 
and presynaptic voltage gated Na+ channels.  
 
Discussion 
PregS increasess [Ca2+]i and activates CREB at picomolar concentrations via a novel 
mechanism 
 We determined that PregS induces an increase in [Ca2+]i with an EC50 of 2 pM 
(95% confidence interval 1 - 5 pM, Hill slope 0.7 ± 0.2). This effect of PregS in neurons 
represents an increase in potency by 7 orders of magnitude compared to PregS 
potentiation of NMDA-induced currents in chick spinal cord neurons (EC50 = 57 %M; Wu 
1991).  An effect of PregS with such high potency likely reflects a novel high-affinity 
binding site for PregS that is on or associated with a protein that plays a role in regulating 
[Ca2+]i. Furthermore, this concentration range is below the most sensitive detection limit 
for PregS in rat brain (~100pM, Ebner 2006), and suggests that endogenous PregS 
modulation of synaptic transmission may occur in vivo. Compounds with a saturated B-
ring also had minimal effect on [Ca2+]i, levels, and addition at the 3-carbon hydroxyl of a 
negatively charged succinate (PAHS) or sulfate (PAS) did not restore activity. These 
results indicate that a C5-6 double bond in the B-ring and a negatively charged group at 
the 3-carbon hydroxyl position is necessary for steroid-induced [Ca2+]i increases in 
primary cortical neurons in the picomolar concentration range.  The lack of effect of the 
GABA-potentiating pregnan series (PA, PAS, PAHS) argues against 50pM PS 
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disinhibition of synaptic activity by inhibiting GABAAR tone, and suggests that 50pM 
PregS is potentiating excitatory synaptic activity.  
 We also demonstrate that 50pM PregS induces a 44 ± 13% increase in levels of 
pCREB, which provides supporting evidence that picomolar concentrations of PregS are 
sufficient to induce physiologically relevant downstream responses to extracellular 
signaling.  PAS did not induce pCREB increases, indicating that a C5-6 double bond is 
required for both 50pM PregS-induced [Ca2+]i and pCREB increases. Interestingly, 
DHEAS had no effect on pCREB, indicating that while a C3 negative charge and C5-6 
double bond are required for the [Ca2+]i effect, there is an additional conformational 
restraint at the C17 carbon group for the pCREB effect, for instance, the longer C17 
acetyl group in PregS may be required for interaction with an amino acid in a binding 
site. If the binding site for 50pM PregS responsible for 50pM PregS [Ca2+]i and 
downstream activation of CREB is the same, a pharmacaphore capable of enacting these 
responses will have the same charge and geometry constraints of a planar molecule with 
steroid nucleus, C3 negative charge, and C17 acetyl group. The structural mimetics 
PAHS and PHS (for PAS and PS, respectively) carry a negative charge at the C3 carbon, 
however the succinate group is not readily cleaved by sulfatases. While PAHS had no 
effect, PregHS increased [Ca2+]i and pCREB, indicating that development of a compound 
mimicking PregS while avoiding inclusion of a labile C3 sulfate is possible.  
  
PregS induced [Ca2+]i and pCREB increase is contingent upon NMDAR-mediated 
excitatory synaptic transmission 
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 Results of our experiments are consistent with a requirement for synaptic activity in 
the high potency of PregS effects. For instance, if PregS were acting directly on 
presynaptic terminal calcium, TTX would not be expected to block the effect of PregS on 
[Ca2+]i levels.  Block of PregS induced [Ca2+]i increase by the NMDAR antagonist DAP5 
and inhibition of PregS-induced pCREB increase by blockade of synaptic NMDARs with 
BIC/MK801 further supports the requirement for synaptic activity in the PregS effect on 
[Ca2+]i levels and pCREB, respectively. We also determined that the Ca2+L blocker 
nifedipine blocks PregS induced [Ca2+]i increases, which is consistent with an 
extracellular source of Ca2+ for the response. These findings are in line with previous 
work demonstrating a link between Ca2+L activation and increases in pCREB levels 
(Dolmetsch 2001). Although store-operated calcium channels (SOCC) are known to play 
a role in modulation of intracellular calcium (Zakharov 2004), our results do not support 
SOCC involvement in PregS induced [Ca2+]i increases.  As there are numerous pathways 
by which pCREB is activated by extracellular signals (Shaywitz 1999), we sought to 
determine which pathway was involved in PregS-induced pCREB increases. We 
observed that pM PregS induces ERK phosphorylation, and that inhibition of MAPK 
blocks PregS activation of CREB, implicating the MAPK pathway in PregS induced 
pCREB increases via modulation of synaptic transmission. Inhibition of CamKII did not 
eliminate the effect of PregS, and although we can rule out other pathways leading to 
pCREB activation, the complete inhibition of the effect of PregS on pCREB levels by 
MAPK blockade makes this scenario unlikely.  
 50pM PregS is sufficient to induce increases in pCREB, a physiological response 
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critical for learning and memory.  It is also known that PregS can be released in a 
retrograde messenger-like fashion to increase presynaptic glutamate release (Mameli 
2005).  This raises the possibility that endogenous release of PregS at concentrations as 
low as 50pM could augment synaptic plasticity in cultured cells.  A possible future 
direction for the research could be to determine the role of pM PregS in LTP.  A 
previously validated method of chemically-induced LTP (Molnar 2011) could be used to 
determine if increasing extracellular PregS by sulfatase inhibition (Babalola 2012) may 
play a role in synaptic plasticity. Additionally, if release of PregS is required for  LTP we 
would expect that treatment with a sulfatase inhibitor such as DU-14 (Babalola 2012) 
would potentiate LTP. Consistent with a role for endogenous neurosteroids in synaptic 
plasticity, previous studies have shown that blocking aromatase production of estradiol 
inhibits high-frequency stimulation induced LTP in rat vestibular brain slices (Grassi 
2009).  PregS increases in EPSP frequency in rat CA1 pyramidal cells are NMDAR-
dependent and can be eliminated using a PregS-specific antibody to scavenge 
extracellular PregS (Mameli 2005). Blocking P450scc activity inhibits long-lasting 
potentiation in rat dentate gyrus, which can be rescued by PREG, DHEA and DHEAS 
treatment of the slice at nanomolar concentrations (Tanaka 2012).  
 While the endogenous role of PregS in modulating synaptic activity remains an area 
of open investigation, our results show that low pM concentrations of PregS induce 
[Ca2+]i and pCREB increases in a manner that requires excitatory synaptic transmission 
and is contingent upon NMDAR activation. Further investigation of high potency PregS 
modulation of excitatory synaptic transmission may yield novel molecules useful in the 
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treatment of cognitive deficits associated with neurological disorders.  
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Appendix I 
N-acetylcysteine, a thiol inhibitor of oxidative stress, stabilizes the spontaneous 
release of neurotransmitters from striatal synaptosomes and stimulates 
depolarization-induced release of newly accumulated [3H]dopamine4 
 
Abstract 
 Oxidative stress may contribute to the pathogenesis of diverse CNS disorders, 
including Parkinson’s disease and stroke. N-acetylcysteine is an endogenous thiol-
containing antioxidant used as an adjunctive treatment for symptoms associated with 
schizophrenia and bipolar disorder, presumably by stabilizing neurotransmission. 
Neurotransmitter release from synaptic sites is inactivated in part via reuptake into 
presynaptic terminals where it is selectively repackaged into a releasable pool of 
transmitter. To determine whether oxidative stress might play a role in neurotransmitter 
release, we double-labeled synaptosomes and synaptoneurosomes derived from the rat 
striatum with two transmitters bearing either a 14C or 3H radiolabel ([3H]dopamine + 
[14C]glutamate, or [3H]GABA + [14C]glutamate) via high affinity transport and asked 
whether NAC alters spontaneous and/or depolarization-induced release of newly 
accumulated transmitter. We observed that N-acetylcysteine (500 µM) increases the 
uptake of [3H]dopamine and [14C]glutamate, reduces and stabilizes the rates of 
spontaneous transmitter release, and increases K+ (10mM) depolarization-induced release 
                                                
4 Smith, CC*, Whittaker, MT*, Gibbs, TT, Farb, DH Manuscript in preparation 
*Co-first authors 
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of [3H]dopamine. The results indicate that N-acetylcysteine, an inhibitor of oxidative 
stress, can stabilize spontaneous transmitter release and increase depolarization-induced 
release of dopamine from nigro-striatal terminals, a finding of potential importance to the 
treatment of Parkinson’s disease. 
 
Introduction 
Reactive oxygen species (ROS) have been linked to neurodegenerative disorders ranging 
from Alzheimer's to Parkinson’s disease. (Halliwell 2001 and Martin 2009). However, 
endogenous ROS such as superoxide and nitric oxide (NO) can also modulate 
neurotransmission (Brennan 2009; Garthwaite 2008; Girouard 2009) and may play 
critical roles in the neural processes involved in synaptic plasticity and memory 
formation (Kishida 2007). It has been shown that superoxide scavengers block induction 
of long term potentiation (LTP) while superoxide production occludes high frequency 
stimulation-induced LTP (Klann 1998; Klann 1998, Knapp 2002), and mice 
overexpressing the superoxide scavenging enzyme superoxide dismutase (SOD) are 
deficient in behavioral measures of learning and memory (Levin 1998).  
 ROS also play a role in striatal neurotransmitter release. In hippocampal 
synaptosomes, lower concentrations of NO increase production of cyclic guanosine 
monophosphate (cGMP) and inhibit glutamate (GLU) release, while higher NO 
concentrations reverse GLU transport and markedly elevate GLU release (Sequeira 
1997). ROS may also affect extracellular DA and GLU levels by inducing oxidative 
damage of their transporters (Chen 2007; Whitehead 2001). 
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 Isolated nerve terminals (synaptosomes) are a well-characterized model system 
uniquely suited for the study of neurotransmitter release (Raiteri and Raiteri 2000), yet 
the impact of oxidative stress on the underlying stability of this preparation has not been 
explored. Striatal DA terminals are prime targets for oxidative damage given the auto-
oxidation potential of DA and the formation of DA quinone, which reacts with O2 to form 
superoxide radical anion and, left unchecked, can produce a feedback loop of increasing 
neural damage (Halliwell 2001; Bagh 2008). Oxidation of the thiol group in cysteine 
residues of proteins impairs neuronal function by inhibiting the activity of mitochondrial 
complex I (Martinez 1996) and alters signaling between neurons (Oja 2000; Lipton 
2002). Thiols are capable of being reversibly oxidized and are essential for the 
maintenance of reducing/oxidizing (redox) balance within cells (Moran 2001). The thiol 
glutathione (GSH), a tripeptide that maintains a reducing environment within cells, can 
be elevated therapeutically with the GSH precursor n-acetylcysteine (NAC) (Moran 
2001). NAC, which shifts cytosolic GSH to a reduced state (Russell 1994; Aoyama 
2006), directly scavenges free radical species (Bagh 2008) and has been found to have 
neuroprotective properties in several experimental models (Martinez 1999; Butterfield 
2003). 
 Given the possibility that oxidative damage to terminals can increase the rate of 
spontaneous [3H]DA and [14C]GLU release, this study was designed to determine whether 
the presence of antioxidant compounds influences neurotransmitter release from nigro-
striatal synaptosomes/synaptoneurosomes (SSNs). We assessed the effects of NAC (500 
µM) on differential rates of uptake of two transmitters bearing 14C or 3H radiolabel 
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([3H]DA + [14C]GLU, or [3H]GABA + [14C]GLU), and measured spontaneous and K+ 
(10mM) depolarization-induced release. The results show that the thiol antioxidant NAC 
enhances [3H]DA and [14C]GLU uptake, reduces spontaneous [3H]DA, [14C]GLU and 
[3H]GABA release, and stimulates depolarization-induced release of [3H]DA from striatal 
SSNs.  
 
Materials and Methods 
Subjects 
Male Sprague-Dawley rats (225-300 g) from Charles River Laboratories (Wilmington, 
MA, USA) were housed in shoe-box cages (2 rats/cage) kept in a temperature-controlled 
room with a 12-hour light/dark cycle. All experiments were performed during the light 
cycle, and the animals were provided with food and water ad libitum. All procedures 
were carried out under a protocol approved by the Boston University School of Medicine 
Institutional Animal Care and Use Committee. 
 
Materials 
[7,8-3H]DA ([3H]DA: 45 Ci/mmol), L-[U-14C]GLU ([14C]GLU: 253 mCi/mmol), and 4-
amino-n-[2,3-3H]butyric acid ([3H]GABA: 94 Ci/mmol) were from Amersham 
(Buckinghamshire, UK). Chemicals used in preparation of tissue for electron microscopy 
were purchased from Electron Microscopy Sciences (Hatfield, PA, USA). All other 
chemicals were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA).  
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Synaptosome/synaptoneurosome (SSN) preparation  
SSNs were prepared according to the methods of Pittaluga et al. (2001) with minor 
modifications as previously described (Whittaker 2008). Rats were decapitated and brains 
removed immediately.  Striatal tissue was dissected out and placed in 12 ml of ice-cold 
homogenization buffer (320 mM sucrose, 4 mM sodium phosphate buffer, pH 7.4). 
Tissue was homogenized by 12 strokes in a motor-driven glass-Teflon homogenizer at 
4°C, and centrifuged for 10 min at 1,000 g. The supernatant (S1) was removed and 
centrifuged at 12,000 g for 20 min. The resulting pellet (P2) was resuspended in 12 ml 
ice-cold homogenization buffer and recentrifuged for 20 min at 12,000 g to obtain the 
final SSN pellet.  
 
Electron microscopy  
Percoll-purified striatal SSNs were fixed in 4% paraformaldehyde plus 0.1% 
glutaraldehyde in artificial cerebrospinal fluid (aCSF) for 1 h at 4°C. The SSNs were then 
pelleted by centrifugation at 3,000 rpm (480 g) for 2 min in a benchtop centrifuge 
(Shelton Scientific, model VSMC-13) and exposed to 3 x 5-min washes in ice cold Mg2+-
free aCSF. The pellet was resuspended for each wash step. Next, the SSN pellet was 
incubated with 4% osmium tetroxide/1.5% potassium ferrocyanide for 2 h at 4°C. The 
pellet was dehydrated through an increasing ethanol series, washed 3 x 10 min with 
propylene oxide, covered in Epon-Araldite embedding mixture and left overnight at room 
temperature. The embedding mixture was replaced and the pellet was incubated for 48 h 
at 60°C. 90-100 nm sections of the embedded SSN pellets were cut using an 
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ultramicrotome (Ultratome Nova LKB2188). Sections were mounted on copper grids and 
counterstained with 1% uranyl acetate in 100% methanol and viewed with a transmission 
electron microscope (Jeol 1200) at 60 keV. Sections of SSN pellets were examined at 
10,000x magnification. All of the structures containing synaptic contacts were 
characterized as synaptosomes (intact presynaptic terminal, synaptic junction, and 
ruptured postsynaptic element) or synaptoneurosomes (intact pre- and postsynaptic 
elements). 
 
Radiolabeled neurotransmitter uptake experiments   
The SSN pellet was resuspended in ice-cold, Mg2+-free aCSF immediately prior to 
experimentation and loaded by incubation with 20 nM [3H]DA, 20 nM [3H]GABA, or 2.9 
!M [14C]GLU for 15 min at 37°C. In dual-label experiments SSNs were loaded with 
[3H]DA or [3H]GABA, plus [14C]GLU and release of each compound was determined by 
double-label scintillation counting (Bransome 1985). Double-label scintillation counting 
is advantageous because it enables release of two different neurotransmitters to be 
measured at exactly the same time, in exactly the same preparation, and under exactly the 
same conditions, reducing variability and increasing power, while doubling the amount of 
data obtained from each preparation, resulting in more efficient use of animals as the 
preparation serves as its own control. 
Specific uptake was confirmed for each experiment in a parallel assay that compared the 
uptake at 37°C to that at 0°C. NAC was included in the uptake medium only in 
experiments in which it was included in the superfusion medium. Radiolabeled 
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neurotransmitter uptake was carried out in –NAC buffer in all other experiments. Equal 
volumes of the loaded SSNs were then introduced between two Whatman GF/B filters (8 
mm diameter) in each of six parallel superfusion chambers in a Brandel suprafusion 
apparatus (Model SF-06, Brandel, Gaithersburg, MD, USA). SSNs were perfused with 
continuously oxygenated Mg2+-free aCSF at a rate of 0.6 ml/min at 37°C.  
 100 µM pargyline (monoamine oxidase B inhibitor) was included in the perfusion 
buffer in experiments that examined [3H]DA release. Antioxidants and other 
pharmacological agents were included in the superfusion buffer throughout the 
experiment, unless otherwise specified. After a 15 min initial perfusion period, 1-min 
fractions were collected from t = 15 to 35 min. A 2 min pulse of 13 mM KCl (10 mM 
NaCl replaced with 10 mM KCl) was applied starting at t = 32 min (KCl) to study 
stimulus-induced transmitter release in some experiments. At the conclusion of each 
experiment, filters containing immobilized SSNs were collected and lysed with 0.6 ml 
0.1 M perchloric acid. The radioactivity present in the perfused SSNs retained on the 
filters, and in perfusate fractions collected, was determined by liquid scintillation 
counting as in the uptake experiments described above. All experiments were completed 
within 4 hours of harvesting the rat brain. 
 
Fractional transmitter release calculation   
The amount of radiolabeled neurotransmitter released during each 1-min collection 
interval was expressed as a percentage of the total radioactivity present at the time of 
fraction collection, referred to as ‘fractional release’ (Sanz et al. 2000). Total 
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radioactivity was computed as the sum of released radioactivity present in all fractions 
prior to the sample of interest, plus the radioactivity remaining at the conclusion of the 
experiment. 
 Both control and drug treatment trials were carried out in triplicate. Therefore, for 
a single experiment (n=1), the fractional release value for each time point represents the 
mean release value of three separate perfusion trials carried out in parallel. In all traces 
and histograms, data points represent mean ± SEM from n independent experiments 
carried out in triplicate.  
A single mean spontaneous transmitter release value for both control and 
experimental trials was calculated by computing the average fractional release value for 
time points corresponding to t = 16 –19 min. Mean spontaneous release values reported 
in histograms and tables represent the mean ± SEM of the individual mean values 
calculated for n independent experiments 
KCl-evoked transmitter release was calculated as the cumulative percentage 
increase over baseline values of a pre-determined series of time points after the stimulus, 
which is a measure of the area under the curve. 10 mM KCl was applied as a 2 min pulse 
from t = 32–34 min. The effect of KCl application was calculated using the points 
corresponding to t = 32–35 min. Percent increase over baseline values for each point in 
the peak were calculated using the formula: % increasex = ((FRx-
baseline)/baseline))!100; where ‘FRx’ refers to the fractional release value of a single 
point in the peak, and ‘baseline’ corresponds to the mean release value for t = 28–30 min. 
Statistical analysis 
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Statistical analysis of experiments comparing the effects of multiple drug treatments on 
spontaneous transmitter release or induced transmitter release was performed using one-
way ANOVA, followed by Tukey’s honestly significant differences test. Repeated 
measures ANOVA was used to assess the effect of switching from +NAC to –NAC 
perfusion buffer on spontaneous transmitter release. The fractional release values for each 
point after switching were compared to the value of the time point immediately prior to 
switching by Dunnett’s multiple comparison test to assess the time course of the effect of 
NAC removal. The effects of KCl application on neurotransmitter release were 
considered statistically significant if the lower 95% confidence limit of the mean was > 0. 
Student’s 2-tailed t-test for independent samples was used in comparisons between two 
separate groups. In all analyses, a p-value of less than 0.05 was considered statistically 
significant. 
Results 
Two independent SSN preparations were examined by electron microscopy and found to 
contain numerous intact, sealed synaptic terminals with mitochondria, clear synaptic 
vesicles, and attached postsynaptic elements (Fig. 28). Structures in 13 fields containing 
synaptic contacts were characterized, and axon terminals were found to range in size 
from 0.2 µm ~ 1.5 µm in diameter. The observed synaptic terminals were comprised of 
synaptosomes (40 ± 6% of total synaptic junctions), characterized by an  
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Fig. 28. Standard preparations of “synaptosomes” from the striatum contain a 
mixture of synaptosomes and synaptoneurosomes. (a) Glutamatergic and 
dopaminergic terminals commonly synapse with the head and neck, respectively, of the 
same spine of striatal medium spiny neurons in the intact striatum (Smith et al. 2000; 
2004). (b) Immunocytochemical staining of a sample of the crude SSN preparation 
reveals structures expressing the presynaptic protein bassoon (green) apposed to the 
postsynaptic protein PSD-95 (red) (arrows). (c) Electron micrograph of a representative 
section through the crude SSN pellet shows the presence of a synaptosome (At1, intact 
presynaptic terminal, synaptic junction, ruptured postsynaptic element) and a 
synaptoneurosome (At2, intact presynaptic terminal, synaptic junction, intact postsynaptic 
element). Intact synaptic contacts are indicated by arrowheads. Asterisk indicates the 
intact postsynaptic element present in the synaptoneurosome. (d) Model of the 
distribution of SSNs in a superfusion chamber based on relative abundance of specific 
neuron terminal populations in striatal tissue. SSNs are proposed to be arranged as a layer 
20-40 %m in thickness. Work completed by M. Whittaker 
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intact presynaptic terminal, synaptic junction, and ruptured postsynaptic element; and 
synaptoneurosomes (60 ± 6% of total synaptic junctions), characterized by intact pre- and 
postsynaptic elements, leading to our use of the term SSNs (synaptosomes and 
synaptoneurosomes). 
 Studies of perfused SSNs report that neurotransmitters released from synaptic 
terminals are unable to interact with presynaptic autoreceptors or nearby postsynaptic 
elements. The reasoning is based on the observation that receptor antagonists do not alter 
spontaneous or evoked transmitter release, thus positing that rapid superfusion with 
physiological saline removes endogenous transmitters before they can interact with other 
terminals (Raiteri and Raiteri 2000). However, our calculations of synaptosome density 
using similar amounts of protein indicate that synaptic and non-synaptic interactions may 
be more likely than previously appreciated. Typically, 200 µg SSN protein is loaded per 
superfusion chamber. Using a conversion factor of 10:1, the volume of this tissue is 
calculated to be 0.002 cm3 (Paczynski 2000). The surface area of the filter on which the 
terminals are immobilized inside the superfusion chamber is 0.50 cm2, which gives an 
average estimated thickness of 20–40 µm for the SSN layer. Analysis with transmission 
electron microscopy showed that the average diameter of striatal SSNs in the preparation 
is approximately 1 µm (Fig 28c), with many nearby profiles showing characteristics of 
pre- and postsynaptic elements. Glutamatergic terminals comprise the large majority of 
axon terminals present in striatum, whereas DA terminals comprise ~10-15% of striatal 
axon terminals (Ingham 2004). GABAergic and cholinergic interneurons represent ~2% 
and 1% of the total striatal neuron population respectively (Tepper and Bolam, 2004). 
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This suggests the potential for interaction among the differing receptors present on 
terminals from multiple neuronal types within each perfusion chamber. 
 In light of the hypothesized arrangement of SSN terminals within the superfusion 
chamber (Fig 28d), it is possible that GLU released from cortico-striatal terminals could 
lead to increased Ca++ influx and elevation of oxidative state inside synaptic elements 
(Coyle and Puttfarcken 1993; Monje 2000; Bonde 2005; Girouard 2009). Striatal DA 
terminals are particularly susceptible to conditions of oxidative stress, given the extensive 
afferent GLU input to the striatum (Bonde 2005; Girouard 2009; Monje 2000), and the 
ability of DA to react spontaneously with O2 to generate superoxide radical anion, H2O2, 
and reactive quinones/semiquinones that can deplete glutathione and bind to protein-thiol 
groups (Stokes 1999; Bagh 2008). We examined whether the application of thiol-
containing antioxidant compounds such as NAC and whether antagonists of GLU action 
at NMDA receptors could influence the basal release of [3H]DA from striatal SSNs. To 
assess whether spontaneously released GLU might act via NMDARs to stimulate 
spontaneous [3H]DA release, D-AP5 (an inhibitor of synaptic and extrasynaptic 
NMDARs) was used as a probe for GLU-induced NMDAR activation. D-AP5 decreases 
spontaneous [3H]DA release by 58% , demonstrating the existence of spontaneously 
occurring interactions between released transmitter and NMDARs. Notably, 
depolarization-induced release as a fraction of baseline release was increased by 152% in 
the presence of D-AP5 (Table 6).  
 Increased neurotransmitter release could result from a decrease in 
neurotransmitter reuptake or an increase in neurotransmitter release from presynaptic  
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Table 6 
 
Mean fractional release values were calculated by computing the average of the fractional [3H]DA release 
values for points corresponding to t = 16 - 19 min for each condition. Depolarization-induced release values 
were calculated as described in Materials and Methods. n refers to the number of replicate experiments 
carried out in triplicate. Statistical analyses were completed by one-way ANOVA followed by Tukey's 
HSD. *p < 0.05, **p < 0.001 vs. control. #p < 0.05 vs. KCl + DAP-5.  Work completed by M. Whittaker 
 
Condition Target
Mean fractional 
release (n)
% change 
from control
Induced release 
(n)
% change from 
control
Control ---- 6.2 ±  0.4 (10) --- 240 ±  25 (10)# ---
+500 µM NAC free radicals 1.4 ±  0.1 (4)** -78% 368 ±  23 (4)*# 53%
+500 µM NAC + 100 µM Vit E free radicals 1.4 ±  0.1 (3)** -77% 356 ±  28 (3)*# 48%
+100 µM D-AP5 NMDAR 2.6 ±  0.2 (10)** -58% 604 ±  38 (10)** 152%
1mM glutathione free radicals 0.9 ±  0.1 (3)** -85% nd
Summary of spontaneous and depolarization induced [3H]DA release values
Spontaneous [3H]DA release Depolarization induced [3H]DA release
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terminals. SSNs were incubated with radiolabeled DA and GLU in order to determine if 
antioxidants could influence the kinetics of DA or GLU transport. Specific uptake of 
[3H]DA and [14C]GLU was enhanced in the presence of NAC (Fig. 29). In a 12 min 
uptake period NAC increased specific uptake of [3H]DA 3.5-fold (from 4 ± 1 pmol/mg to 
14 ± 1 pmol/mg), and [14C]GLU 5.8-fold (from 185 ± 23 pmol/mg to 1,065 ± 125 
pmol/mg) (Fig 29). One hypothesis is that increased [3H]DA and [14C]GLU uptake in the 
presence of NAC reflects decreased [3H]DA and [14C]GLU release. NAC may result in 
these changes via specific modulatory actions or by preserving the integrity of isolated 
terminals against damage due to oxidative stress.  In this case, NAC would be expected to 
decrease spontaneous release of  [3H]DA and [14C]GLU and could also increase 
depolarization-induced release due to an increase in the proportion of transmitter in a 
readily releasable pool. 
 Superfusion experiments were designed to test the effects of NAC on spontaneous 
and depolarization-induced (2 min pulse with 10 mM KCl) release of [3H]DA and 
[14C]GLU to study whether the antioxidants modulated the process(es) for 
neurotransmitter release. Basal release of [3H]DA and [14C]GLU was dramatically 
reduced and stabilized when NAC was present throughout perfusion. Net KCl-stimulated 
fractional release was also reduced in the presence of NAC (Fig. 29a,b), but to a lesser 
extent than spontaneous release, and depolarization-induced release relative to baseline 
was increased in the presence of NAC. As shown in Fig. 29a, b, spontaneous release of 
[3H]DA was decreased by 78% and depolarization-induced DA release (10mM KCl) was 
increased by 53% relative to baseline (Fig 29c,d) in the presence  
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Fig. 29. NAC increases specific uptake of [3H]DA and [14C]GLU in double labeled 
striatal SSNs. (a) Left panel: 500mM NAC enhances the specific uptake of [3H]DA. 
Right panel: [3H]DA uptake is significantly enhanced after 12 min of incubation in the 
presence of NAC (**p < 0.01 compared to control; Student's t-test for independent 
samples). (b) Left panel: 500mM NAC increases the specific uptake of [14C]GLU. Right 
panel: [14C]GLU uptake is significantly elevated after 12 min of incubation in the 
presence of NAC (***p < 0.0001 compared to control; Student's t-test for independent 
samples). Specific uptake of radiolabeled transmitter was calculated as total uptake – 
nonspecific uptake (see Methods). Each data point is the mean ± standard erorr of the 
mean of 3 to 4 independent experiments carried out in triplicate. Uptake data was fit to 
the equation . Work completed by C. Smith 
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Fig. 30. NAC decreases spontaneous release and augments depolarization-induced 
release of [3H]DA and [14C]GLU from double labeled striatal SSNs. Traces showing 
spontaneous release of [3H]DA (a) and [14C]GLU (b) from striatal SSNs. Open circles: (-
)500µM NAC, closed circles: (+)500µM NAC. (c) NAC significantly lowers mean 
spontaneous [3H]DA release and [14C]GLU release from striatal SSNs (***p < 0.0001 
compared vs. control; Student’s t-test for independent samples). (d) Right panel: NAC 
significantly enhances 10mM KCl-induced [3H]DA and [14C]GLU release from striatal 
SSNs (**p < 0.01 compared vs. control; Student’s t-test for independent samples). n = 
number of independent experiments carried out in triplicate. Work completed by M. 
Whittaker 
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of NAC. Similarly, spontaneous [14C]GLU release was decreased by 83%, while 10 mM 
KCl-induced [14C]GLU release was increased by 84% relative to baseline (Fig 30c,d) in 
the presence of NAC.   
 To test whether the effect of NAC on spontaneous neurotransmitter release is 
specific for [3H]DA- and [14C]GLU-containing terminals, its effect on spontaneous 
[3H]GABA efflux was examined. NAC reduced mean spontaneous [3H]GABA release by 
52% vs. control while lowering mean spontaneous [14C]GLU release to a similar degree 
as spontaneous [3H]DA release ([14C]GLU: -83%, [3H]DA: -78%) (Table 6). 
 We next tested whether the effect of NAC on [3H]DA is reversible. After 20 min 
of perfusion with aCSF + NAC, the perfusion buffer was switched to aCSF alone. 
Spontaneous [3H]DA and [14C]GLU release increased following NAC washout (5 and 6 
min after removal of NAC, respectively) (Fig. 31). Analysis of data points from t = 20 – 
28 min by repeated measures ANOVA indicated a significant effect of NAC removal on 
spontaneous [3H]DA release [F(14,3)= 15.9, p < 0.0001]. Post hoc comparison of each 
data point from t = 21– 28 vs. t = 20 (final point before switch) indicated a significant 
increase in [3H]DA release beginning at t = 25 min (Fig. 31a). Analysis of data points 
from t = 20 – 28 by repeated measures ANOVA indicated that in the continued presence 
of NAC there is a small but statistically significant decrease in spontaneous [3H]DA 
release relative to the release observed at t = 20 min, beginning at t = 24 min (p < 0.0001; 
Dunnet’s multiple comparison test; Fig. 31a). Experiments observing the effect of NAC 
removal on spontaneous [14C]GLU release showed a smaller increase in release than for 
[3H]DA upon removal of NAC (Fig. 31). Analysis of data points from t = 20 – 28 min by  
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Table 7 
 
  
 
 
 
 
Work completed by M. Whittaker 
[3H]DA (n) [14C]glutamate (n) [3H]GABA (n)
Control 6.2 ±  0.4 (10) 7.3 ±  0.5 (3) 5.2 ±  0.6 (3)
+500 mM NAC 1.39 ±  0.1 (4)** 1.4 ±  0.1 (4)** 2.5 ±  0.1 (8)**
Mean spontaneous fractional release values from striatal SSNs
Mean fractional release values correspond to t = 16 - 19 min for each 
condition. N refers to the number of replicate experiments carried out in 
triplicate. 
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Fig. 31. Inhibition of [3H]DA and [14C]GLU release from double labeled striatal 
SSNs by NAC is reversible. Removal of NAC from the superfusion buffer triggers a 
large increase in [3H]DA and [14C]GLU release from double labeled striatal SSNs. Traces 
represent fractional transmitter release from striatal SSNs perfused with aCSF +NAC 
(closed circles) or aCSF –NAC (open circles). (a) Switching of the perfusion buffer from 
+NAC to –NAC containing buffer at t = 20 min (indicated by arrow) results in increased 
spontaneous [3H]DA release (Dunnet’s Multiple Comparison Test, *p < 0.05; **p < 0.01, 
**p < 0.0001). (b) Switching of the perfusion buffer from +NAC to –NAC containing 
buffer at t = 20 min (indicated by arrow) results in increased spontaneous [14C]GLU 
release (Dunnet’s Multiple Comparison Test, *p < 0.05; ***p < 0.0001). There was no 
change in spontaneous [14C]GLU release in the continued presence of NAC.  n = number 
of independent experiments carried out in triplicate. Work completed by C. Smith and M. 
Whittaker 
  
 131 
repeated measures ANOVA indicated a significant effect of NAC removal on 
spontaneous [14C]GLU release [F(14,3)= 32.97, p < 0.001]. Post hoc comparison of each 
data point from t = 21– 28 vs. t = 20 min (final point before switch) indicated a 
significant increase in [14C]GLU release beginning at t = 24 min (Fig. 31b). 
 Thiol-containing antioxidants function principally by protecting exposed thiol 
groups from oxidation and by direct scavenging of free radicals (Dringen 2000). 
Conditions of oxidative stress in neurons gives rise to ROS such as O2-, HO•, NO, H2O2 
that can deplete glutathione, bind to protein thiol groups and cause lipid peroxidation. We 
sought to further elucidate how NAC may be interacting with these free radicals to 
stabilize DA release.  
 NMDA receptor activation can increase NO production by neuronal NO synthase 
(nNOS) (Girouard 2009), and NO is known to stimulate striatal DA release (Trabace 
2000). Additionally, the reaction of NO with superoxide results in the formation of 
peroxynitrite (Vriesman 1997), which plays a critical role in oxidative damage (Pacher 
2007). Accordingly, NO scavengers attenuate toxic effects of NMDA on extracellular 
DA levels in vivo (Smith and Whitton 2001). We hypothesized that NAC may reverse 
oxidative damage by scavenging extracellular NO, and that inhibition of NO production 
would mimic the stabilizing effect of NAC on [3H]DA release in striatal synaptosomes. 
In order to determine if NO increases spontaneous [3H]DA and [14C]GLU release from 
SSNs, nNOS was blocked using 100mM L-N-nitroarginine (L-NNA) (Klatt 1994), which 
unlike L-NG-nitroarginine methyl ester (L-NAME), does not require hydrolysis by 
intracellular esterases to achieve its active form. L-NNA lowers spontaneous [3H]DA 
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release by 34% relative to control (vs. 78% for NAC), but did not lower [14C]GLU release 
to a statistically significant extent (Fig 32). L-NNA potentiated 10mM KCl-induced 
[3H]DA release (1344% increase), but had no effect on 10mM KCl-evoked [14C]GLU 
release.  
 The lower efficacy of NOS inhibition compared to NAC in lowering spontaneous 
[3H]DA release leads to the hypothesis that other ROS in addition to NO may contribute 
to unstable neurotransmitter release. Additionally, removal of NO by NOS inhibition 
resulted in a much greater potentiation of KCl evoked DA release than observed in the 
presence of NAC. NMDAR activation can also lead to formation of superoxide by 
NADPH (Brennan 2009). Therefore, inhibition of NMDARs should reduce superoxide 
production in addition to NO production and subsequent damage to neurotransmitter 
release mechanisms.  
 Other antioxidants were tested to determine if the effect of antioxidants on 
neurotransmitter release is unique to NAC. Inclusion of the lipid soluble antioxidant 
vitamin E with NAC had no additional effect on basal or depolarization-induced [3H]DA 
release (Table 1); however, basal release of [3H]DA was significantly lowered by the 
presence of 1 mM glutathione (GSH) (Table 6).  
 In addition to reducing baseline fractional release and increasing the ratio of 
stimulated to background release, NAC also substantially reduced the variability of 
baseline release (–NAC SD = 2.77; +NAC SD = 0.162; p = 0.00015, 2-tailed F-test). This 
stabilization of baseline spontaneous transmitter release was essential to our ability to 
detect the effect of very low concentrations of PregS on dopamine  
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Fig. 32. Inhibition of nitric oxide synthase decreases spontaneous release and 
increases depolarization-induced [3H]DA release from double labeled striatal SSNs. 
(a) L-NNA lowers mean spontaneous [3H]DA (**p < 0.01 vs. control) but not [14C]GLU 
release (p = 0.16 vs. control) from striatal SSNs. (b) L-NNA significantly enhances 
10mM KCl-evoked [3H]DA release from  striatal SSNs (*p < 0.01 compared to control), 
however, 10mM KCl-evoked GLU release from striatal SSNs remains the same in the 
presence and absence of L-NNA (p = 0.18 compared to control). Statistical tests were 
performed using Student's t-test for independent samples, n = number of independent 
experiments carried out in triplicate. Work completed by C. Smith 
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release from nigro-striatal terminals (Whittaker 2008). In initial experiments examining 
the effect of 25 nM PregS on [3H]DA release in the absence of NAC, we found that 10 
replicate independent experiments (derived from 10 rat brain dissections and SSN 
preparations) with a total of 59 SSN filter runs (each rat brain yields about 6 replicate 
runs per experiment), were required to detect a significant PregS-induced increase in 
[3H]DA release relative to background (–NAC 36 ± 5% increase over background; n = 10 
experiments; p < 0.001). In the presence of 500 µM NAC, a similar SEM and statistical 
significance was attained with 4 experiments with a total 20 filter runs (+NAC 32 ± 4%; 
n = 4 experiments; p < 0.001; Whittaker et al., 2008). The inclusion of NAC therefore 
increased the sensitivity of the measurements by stabilizing spontaneous transmitter 
release and, reducing the number of animals required by 2-3 fold.  
 
Discussion 
Synaptosomal preparations have been used for more than 30 years in thousands of 
publications to provide essential information concerning the underpinnings of 
neurotransmitter function in the central nervous system.  This ex vivo preparation of fresh 
axonal terminals has, however, not to the best of our knowledge, been validated using 
electron microscopy to physically quantify the amount of synaptosomes vs. 
synaptoneurosomes in a standard synaptosomal preparation.  We find that previous 
assumptions of synaptic terminals in the superfusion chamber being a single layer, such 
that released transmitters are washed out too rapidly to affect other terminals, is not 
consistent with the results. Moreover, basal neurotransmitter release from synaptosomal 
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preparations is unstable, but can be stabilized by inhibitors of oxidative stress such as 
NAC, greatly enhancing the sensitivity and reliability of neurochemical determinations.  
 Administration of the thiol-containing antioxidant NAC reduced and stabilized 
the spontaneous release rates of [3H]DA and [14C]GLU in SSNs derived from the rat 
striatum. NAC also increased the uptake of [3H]DA and [14C]GLU as well as K+ (10mM) 
depolarization-induced release of neurotransmitter, findings consistent with previous 
observations of elevated levels of spontaneous [3H]DA release in superfused rat striatal 
SSNs. In addition, addition of 500mM NAC to the aCSF increased [3H]DA and 
[14C]GLU uptake by about 3.5-fold and 5.8-fold (Fig. 29), supporting the observation that 
DA and GLU transporters are sensitive to oxidative damage (Chen 2007; Whitehead 
2001). Both GSH and NAC have shown neuroprotective properties in several models of 
neurotoxicity (Hart 2004; Hsiao 2008; Moschou 2007; Carbonell 2007, Bagh 2008), and 
it is possible that NAC is acting directly on transporters either to potentiate their function 
or to reverse oxidative damage, or by scavenging ROS before transporter function is 
impaired.   
 Inclusion of 1 mM GSH or 500mM NAC in the aCSF dramatically reduced 
spontaneous [3H]DA, [14C]GLU and [3H]GABA release from striatal SSNs (Fig. 30, 
Table 6). DA and GLU terminals maintained their ability to respond to KCl 
depolarization in the presence of NAC (Fig. 30). The potentiation of depolarization-
induced [3H]DA release by NAC is consistent with an increase in [3H]DA uptake (Fig. 
29) and a greater amount of DA in the pool of readily releasable vesicles. Spontaneous 
[3H]DA or [14C]GLU release was significantly increased within 4-5 min of switching 
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from +NAC to –NAC buffer (Fig 31), consistent with evidence that the biological 
processes influenced by NAC are reversible and occur on a rapid time scale (min) (Santos 
1996). The large variability observed in the [3H]DA data set (Fig 31a, upper trace) was 
not observed in the [14C]GLU traces (Fig 31b). This suggests that variability in response 
to switching to –NAC buffer may be specific to DA terminals, perhaps because increased 
oxidation of DA to DA quinone in the presence of hydroxyl radicals (Stokes 1999) 
dramatically increases spontaneous DA release.  
 Inhibition of nNOS also reduced spontaneous release of [3H]DA and [14C]GLU. 
nNOS catalyzes the production of NO from arginine, and NO stimulates release of DA 
and GLU from striatal terminals (Ohkuma 2001). If continuous NO production is 
responsible for high levels of basal DA and GLU release, then scavenging of NO by 
NAC, or inhibition of NOS by L-NNA would be expected to lower spontaneous release. 
However, NO is not the sole ROS responsible for unstable [3H]DA release, as inhibition 
of nNOS did not reduce basal [3H]DA release levels to the same extent as NAC (Fig. 32), 
while depolarization-induced [3H]DA release was greater in the presence of L-NNA than 
NAC. It may be that elevated levels of NO inhibit depolarization-induced DA release, 
while other free radicals such as superoxide potentiate KCl-evoked DA release. 
Consistent with this hypothesis, the large potentiation of KCl-evoked [3H]DA release by 
nNOS inhibition (+1344% L-NNA vs +50% for NAC) is not completely explained by an 
increase in loading vesicular DA. NAC was more effective at lowering spontaneous 
release than was L-NNA (-78% NAC vs. -34% L-NNA), which would be expected to 
result in more DA loaded into the pool of readily releasable vesicles. 
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 Terminals in perfused SSNs are often envisioned as residing in a single layer on 
the microporous membrane, such that transmitter released from individual terminals is 
immediately washed away and unable to influence receptors on nearby terminals (Raiteri 
and Raiteri 2000), but calculations based upon tissue volume and the distribution of 
terminals observed using electron microscopy cast this assumption into question. In view 
of the preponderance of glutamatergic terminals in striatum (Ingham 2004), it is clear that 
there is potential for release of endogenous glutamate to influence release of other 
transmitters. The observation that blockade of NMDARs with D-AP5 substantially 
reduces spontaneous [3H]DA release from superfused striatal SSNs (Table 7) provides 
evidence that endogenous GLU released from cortico-striatal and thalamo-striatal 
terminals stimulates [3H]DA release. This may also have relevance to the function of 
neurons of the striatum, as glutamatergic and dopaminergic neurons commonly synapse 
with the head and neck, respectively, of the same spine of striatal MSNs in the intact 
striatum, so such interactions may recapitulate those that occur in vivo. 
The lowering of spontaneous [3H]DA release and enhancement of depolarization-
induced release (Table 7) by a GLU receptor antagonist is consistent with the hypothesis 
that D-AP5 acts in a neuroprotective manner at DA terminals. The profound enhancing 
effect of D-AP5 on KCl-induced DA release may result from prevention of oxidative 
damage to terminals and vesicular DA transporters, or alternatively, from inhibition of 
postsynaptic NMDAR-mediated release of an inhibitory retrograde signal from the 
population of synaptoneurosomes. Indeed, Schotanus et al. (2006) showed that activation 
of postsynaptic NMDARs inhibits synaptic transmission in striatal slices by stimulating 
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the release of adenosine. 
 One hypothesis is that NAC mediates its effects by acting as a ROS scavenger. 
An alternative hypothesis is that NAC acts extracellularly as a cysteine precursor to 
participate in glial cysteine/GLU exchange (Baker 2003). However, cysteine/GLU 
exchange functions by cysteine entering cells while GLU exits; therefore, NAC would be 
expected to increase and not decrease GLU release. It has been proposed that GSH 
modulates the binding of agonists to ionotropic GLU receptors (Oja 2000), and competes 
for both NMDA (Varga 1989; Ogita 1998) and AMPA/kainate receptor (Varga 1989, 
Jenei 1998) binding sites. This suggests that NAC mediates its release-lowering effect, in 
part, by serving as a precursor for GSH synthesis in neuron terminals, thus inhibiting the 
binding of endogenous GLU released from corticostriatal terminals to ionotropic GLU 
receptors and decreasing spontaneous transmitter release. However, a previous study 
showed significant increases in [3H]DA, [14C]GLU, and [3H]GABA release upon 
application of 300 µM NMDA + 1 µM glycine to SSNs in the presence of NAC 
(Whittaker 2008), suggesting that high concentrations of NMDA can displace bound 
GSH and activate NMDARs.   
 Because NAC reduces basal [3H]DA release to a greater extent than does nNOS 
inhibition, it is likely that NAC scavenges reactive species besides NO. Notably, NAC 
increases [3H]DA and [14C]GLU uptake, suggesting that NAC decreases extracellular DA 
and GLU levels by increasing reuptake along with stabilizing release. Collectively, the 
evidence suggests that GLU released from presynaptic glutamatergic terminals activates 
ionotropic GLU receptors on nigrostriatal DA terminals and corticostriatal GLU 
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terminals, elevating redox states, and that NAC counteracts this effect of oxidative stress 
by acting as a free radical scavenger of NO and superoxide. The concentration of NAC 
used in the present study is within the range of blood levels achieved with therapeutic 
doses (Brown 2004), and NAC readily crosses the blood brain barrier (Farr 2003), 
suggesting that the effects of NAC on neurotransmitter uptake and release may be 
relevant to the therapeutic effects of NAC and other antioxidants.  
 It is unclear whether a high level of ROS-dependent spontaneous release is an 
artifact of the synaptosomal preparation or whether it is relevant to neurotransmitter 
release in vivo. In either case, the results presented here indicate that it is important to 
examine the effect of NAC in order to interpret the mechanism of action of compounds 
that influence neurotransmitter uptake and release. Stabilization of spontaneous release 
increases the sensitivity of the assay system with respect to detecting release that is not 
ROS-dependent, whereas NAC inhibition of the effect of a compound would raise the 
possibility that the compound could be altering release indirectly by influencing ROS 
production, rather than acting directly upon transporters or vesicular release. Failing to 
recognize the destabilizing effect of ROS on synaptic terminal function in this ex vivo 
system may thus lead to erroneous conclusions regarding mechanism of action.  The 
present results suggest that such a confound is likely to have occurred in some of the over 
12,000 publications in PubMed citing the use of synaptosomes. 
 In conclusion, therapeutic doses of NAC can stabilize the spontaneous release of 
DA from disrupted nigro-striatal nerve terminals and increase depolarization-induced 
release. Failure to include ROS scavengers in synaptosomal preparations may result in 
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high, unstable basal neurotransmitter release, which could obfuscate subtle drug effects. 
Looking forward, results from this study point to potential benefits of antioxidants such 
as NAC for the treatment of neurodegenerative diseases such as Parkinson’s based on 
alteration of transmitter release mechanisms (Halliwell 2001; Girouard 2009; Bonde  
2005; Monje 2000). 
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GENERAL CONCLUSIONS 
Chapter 2.  
1. PregS stimulates the addition of functional NMDA receptors to the cell  surface 
membrane during a delayed phase of NMDAR potentiation. 
 
2. PregS delayed potentiation requires G-protein coupled activation of PKC, PLC and 
release of Ca2+ from intracellular stores. 
 
3. The recognition site for PregS delayed potentiation and mechanism of action for PregS 
cognitive enhancing effects require further investigation. 
 
Chapter 3. 
1. PregS induces [Ca2+]i and pCREB increases at pM concentrations via a novel 
mechanism and within the physiological range of endogenous steroid levels. 
 
2. PregS induced [Ca2+]i increases and CREB activation is contingent upon NMDAR-
mediated excitatory synaptic transmission. 
 
3. High potency PregS modulation of [Ca2+]i and pCREB levels is consistent with a role 
for PregS as an endogenous modulator of NMDAR mediated synaptic function resulting 
in long term changes in gene expression. 
 
Appendix I. 
1.  The thiol reducing agent, NAC, reduces and stabilizes spontaneous release of [3H]DA 
and [14C]GLU from rat striatal synaptoneurosome 
 
2. NO is not the sole reactive oxygen species responsible for unstable [3H]DA release 
 
3. Endogenous glutamate release may influence the spontaneous release of [3H]DA via 
stimulation of reactive oxygen species production 
 
4. By stabilizing neurotransmitter release NAC increases the sensitivity of measurments 
on spontaneous transmitter release 
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